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ABSTRACT

Author: Joo, Mindy H. PhD
Institution: Purdue University
Degree Received: August 2018
Title: A Deuterium-Deuterium Neutron Generator-Based Neutron Capture Therapy
System for Brain Tumors
Major Professor: Linda H. Nie
Boron neutron capture therapy (BNCT) is an attractive radiotherapy modality that
utilizes high-LET particles to deliver the radiation dose. Different from conventional
treatments, BNCT has the ability to target tumor cells by injecting patients with a boron10 (B-10) compound that selectively accumulates inside the tumor and irradiating the target
area with a neutron beam. The radiation dose produced is very localized due to the short
travel range of the resulting particles and limited to the B-10 containing cells. The
surrounding healthy tissues receive minimal dose. At present, the BNCT neutron sources
are mainly nuclear reactors and large particle accelerators. These types of neutron sources
have high capital expenses, are difficult to maintain and manipulate, require high voltage,
and cannot be widely installed in clinical settings. A deuterium-deuterium (DD) neutron
generator is a competitive alternative for neutron source due to its low cost, compact size,
low acceleration voltage, and relatively simple installation. The objective of this
dissertation research is to investigate and design a DD neutron generator-based BNCT
system.
In the first study, the optimal neutron energy for BNCT of brain tumors at various
depths was determined. When the neutron source had an energy in the epithermal range,
between 0.5 eV and 10 keV, the dose ratio between the tumor and the brain was maximized.
The alpha dose component accounted for approximately 80% of the total tumor dose. As

xiii
the neutron energy increased to 2.45 MeV, the alpha dose fraction was reduced to 5%. With
an epithermal neutron source, 50% of the total brain dose originated from photons while
neutrons and alphas contributed to the other 50%. Although higher energy neutrons
delivered more dose per source neutron to the tumor, more than 80% of the dose was
deposited by neutrons, and the brain received the same amount of dose as the tumor. The
benefits of the high-LET particles were reduced because the high-energy neutrons were
not thermalized when they reached the tumor site.
The second specific aim focused on designing a beam shaping assembly for a DD
neutron generator source to moderate the fast DD neutrons and reduce radiation
contaminations in the beam. The final optimized layout included a moderator combination
of 45-cm Li7F and 10-cm MgF2, a 30-cm lead reflector, 10-cm lead collimator, and 0.02cm cadmium filter. The neutron spectrum in air had 9.4 x 104 nepi/cm2-s, 0.03 for thermalto-epitherml ratio, 5.9 x 10-13 Gy-cm2/nepi, and 2.1 x 10-13 Gy-cm2/nepi. For the in-phantom
evaluation, the advantage depth (AD) was 12.5 cm, the advantage ratio was 4.4, and the
dose rate at AD was 2.9 x 10-3 cGy-Eq/min. The maximum skin dose was 0.6 Gy-Eq. The
only deficiency of the system was the inadequate neutron flux that DD neutron generators
currently produce.
Finally, the dose distributions of the designed BNCT system in a cadaver-based
phantom were examined in MCNP. The brain obtained a maximum dose of 12.5 Gy-Eq,
minimum dose of 1.2 Gy-Eq, and average dose of 5.3 Gy-Eq. Results from this dissertation
demonstrated the feasibility of a DD neutron generator-based BNCT system for treatment
of brain tumors.
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CHAPTER 1.

1.1
1.1.1

INTRODUCTION AND BACKGROUND

Glioblastoma Multiforme
Epidemiology
Glioblastoma multiforme (GBM) is the most common malignant tumor of the

central nervous system and accounts for more than 60% of all brain tumors and half of all
primary brain tumors in adults, occurring in 2-3 people per 100,000 population.1 Despite
decades of research and advances in treatment techniques, GBM remains an incurable
disease, and patient prognosis and outcomes are extremely poor, with a median survival of
approximately 14-15 months. Less than 5% of patients survive five years after diagnosis.2,3
GBM is classified as the most aggressive and lethal brain tumor and has been designated
Grade IV by the World Health Organization.4,5 Distinct features of GBM from lower grade
brain tumors are necrosis, heterogeneity, and infiltrating proliferation. The incidence rate
of GBM is 1.6 times higher in men than women and 2 times higher in Caucasians than
other races.3 The mean age is 64 years at diagnosis.6 Most GBM occurrences are primary,
and these patients tend to be older and have poorer prognosis than those with secondary
GBM. The only known risk factor for GBM is exposure to ionizing radiation.7
Environmental and occupational exposures, such as to chemical carcinogens and smoking,
have been loosely associated with the development of GBM.
About 61% of GBM occurs in the supratentorial regions of the brain, with the
highest incidence in the frontal lobe, followed by temporal and parietal lobes.8 GBM rarely
occurs in the cerebellum and the spinal cord. Clinical presentations of patients vary greatly
with the size and location of the tumor.9 Common symptoms include increased cranial
pressure, focal neurologic deficits, headache, and seizures.10 Initial diagnosis of the disease
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includes imaging with CT or, most commonly, MRI, where GBM is presented in an
irregularly shaped mass with a necrotic center and surrounded by edema and hemorrhage.
1.1.2

Standard of Care
The main challenges in GBM treatments are the location of the disease and its

complexity and heterogeneity. The current standard of care for GBM patients has not
changed significantly over the past decade and consists of maximally safe surgical
resection of the tumor mass, followed by concurrent and adjuvant chemotherapy with
radiation therapy (RT).11 Surgery is the main component in the management of GBM but,
however, cannot cure the disease completely due to the high degree of invasiveness of
GBM.12,13 GBM is known for its microscopic extension into the surrounding healthy brain
tissues. Thus, the extend of surgical resection is dependent on tumor characteristics and the
location of the involved brain, which is usually in the area that controls speech and motor
functions. After surgery, infiltrating tumor cells will inevitably remain in the brain tissue,
leading to disease progression or recurrence.14 A more extensive surgical resection is
associated with better outcomes but needs to be balanced with the preservation of brain
function.15 Chemotherapy treatment is usually initiated four weeks after surgery. When
combined with other treatment modalities, chemotherapy drug, temozolomide (TMZ), has
been shown to effectively prolong patient survival.12 Concurrently with RT, TMZ is first
administered daily for six weeks. After the conclusion of RT, adjuvant TMZ is restarted
for 12 to 18 months. Prior to 2005, RT alone had been the standard treatment. Later, a study
found that patients who received RT with TMZ showed a significantly increase in the
median survival compared to patients who had only RT (14.6 months versus 12.1 months).5
The current standard RT regimen is typically done with 3D conformal or IMRT beams,
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delivering 1.8-2 Gy per fraction over six weeks for a total dose of 60 Gy to the target.11
The target volume is defined as the volume 2 to 3 cm beyond the tumor mass seen on MRI
or CT scan. Dose escalation has been found to increase radiation toxicity without any
benefits in overall survival.16
1.1.3

Disease Recurrence
Regardless of aggressive multidisciplinary treatment, about 70% of GBM patients

will experience disease progression, and the rate of local recurrence is 80-90%.17,18
Recurrence is very common in GBM due to the proliferation of residual cancerous cells.
Approximately 80% of recurrences occurred within the margins of the first surgery and
RT.5,19,20 Figure 1.1 demonstrates an example of local GBM recurrence. Figure 1.1A shows
the brain image of a GBM patient at diagnosis, and Figure 1.1B is after surgical removal
of the tumor. The patient underwent the standard treatment regimen but experienced
recurrence in the resection cavity 16 months after the first surgery (Figure 1.1C). Prognosis
at recurrence is dismal for patients with recurrent GBM. The estimated medical survival is
9 months, and only 1% live beyond 1 year.21 No standard of care is established for recurrent
GBM patients.22 Treatment options include reoperation, supportive care, and systemic
therapies. Patients with recurrent GBM may undergo a biopsy to rule out radiation necrosis
and be considered for surgery again although the benefits remain unclear. Repeat surgery
may help ease some clinical symptoms that are due to mass effect. Chemotherapy and other
medications can be given to alleviate symptoms and improve quality of life. Re-irradiation
of the disease area is usually not likely because the normal tissues have received the
maximal tolerance dose from previous RT and the incidence of necrosis increases with
dose.
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Figure 1.1 MRI images of a GBM patient showing (A) the tumor in the left occipital lobe,
(B) disease recurrence in close proximity to the surgical cavity and (C) local recurrence
16 months after the initial surgery.23
1.2
1.2.1

Boron Neutron Capture Therapy
Principles
Boron neutron capture therapy (BNCT) is a binary treatment modality that is based

on the nuclear reaction between thermal neutrons and boron-10 (B-10) nuclei (Figure 1.2).
B-10 captures a thermal neutron and then undergoes a fission reaction, releasing an alpha
particle and a lithium ion. The product particles have a very high linear energy transfer
(LET) and short range as compared to conventional radiotherapy photons and electrons
(Table 1.1). The mean travel range of these particles is approximately 10 µm, similar to the
size of a cell. As a result, the radiation dose deposited by these particles is confined to the
cells that are in close proximity to the fission reaction and very localized. BNCT treatment
requires two components: administration of a B-10 carrier compound and delivery of a
neutron beam. Patient is first injected intravenously with a B-10 compound, which
preferentially accumulates in the tumor cells. The target area with the tumor is then
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irradiated with a neutron beam, initiating the fission reaction that generates the heavy
particles. Due to the selective feature of the B-10 compound, a large fraction of the
radiation dose is delivered to the tumor cells while the dose to the surrounding healthy
tissues is minimized. The B-10 compound is nontoxic and nonradioactive until it is
captured by a thermal neutron. While the healthy tissues receive low level of B-10 and nonspecific background dose, the tumor-targeting B-10 compound presents a significantly
greater concentration in the tumors and primarily governs the therapeutic ratio in BNCT.
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Thermal
neutron

10

Li

B

γ
4

He

Figure 1.2 Schematic of boron neutron capture reaction.

Table 1.1 Comparison of LET values of radiation.
Alpha

60

Co Photon Electron (1 MeV)

LET (keV/µm)

150

0.3

0.2

Range (µm)

10

4170

4120

BNCT is a promising modality for treating malignant diseases that have poor
prognosis and response to conventional treatments, such as GBM. As mentioned
previously, GBM is characterized by a primary tumor mass with accompanying
microscopic extensions into the normal brain tissues. Patients with GBM have poor
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prognosis even with advance treatment modalities. Due to the selective accumulation of
the B-10 compound and the characteristics of the high LET particles, BNCT has the ability
to target microscopic tumor cells that current imaging techniques are unable to detect and
conventional therapies fail to eradicate. Attempts to eliminate the invading GBM cells by
extending the resection margins or administering high-dose radiation inevitably lead to
adverse effects.24 BNCT provides not only a physical method of therapy but also has a
biological component that the standard treatments lack.
1.2.2

Background and Early Clinical Studies
Shortly after the discovery of neutron by Chadwick in 1932, the neutron capture

reaction became known to researchers, and it was proposed that such reaction could be
applied to radiation therapy.25-27 Of all the nuclei that have a high tendency for absorbing
thermal neutrons, the isotope B-10 was the ideal element for neutron capture therapy due
to its large capture cross section (Table 1.2) compared to other elements. In addition, B-10
is stable and can be easily incorporated into a variety of chemical compounds. The earliest
BNCT clinical studies were carried out at the Brookhaven Graphite Research Reactor
(BGRR) in 1951. The first 24-month study enrolled ten patients with malignant cerebral
gliomas.28,29 Patients were irradiated with thermal neutrons for 17 to 40 minutes, following
administration of a B-10-enriched borax compound. Although the patients did not exhibit
any serious radiation-induced effect, some experienced borax toxicity. The median survival
of the ten patients was 96 days, similar to GBM patients treated with conventional
therapies.30 The subsequent BNCT series was comprised of nine malignant glioma patients
and used a less toxic B-10 compound, pentaborate.31 However, some patients exhibited
radiation dermatitis of the scalp, sometimes deep ulceration.32 The median survival was
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147 days for the second clinical trial. After the preliminary studies at BGRR, it was
suggested that if a sufficient number of thermal neutrons could reach the tumor site, the
complications from BNCT irradiation may be eliminated. As a result, a high-flux thermal
beam was constructed and operational at the Brookhaven Medical Research Reactor in
1959. However, the clinical results were disappointing: the median survival of the 17
patients after BNCT was only 3 months. At around the same time, a separate study was
carried out at the Massachusetts Institute of Technology (MIT) reactor, where 17 patients
were irradiated. The median survival was 5.7 months, but brain edema and necrosis were
observed within a few months.33,34 Due to a lack of evidence of substantial improvement
in patient survival, all BNCT clinical trials were suspended in the United States in 1961.
The renewal of BNCT investigations resumed in Japan in 1968 and presented promising
results, where the 5 year survival rate was 58%.35 The common BNCT practice in Japan
was to apply intraoperative radiotherapy, exposing the tumor bed directly to the radiation
beam after tumor excision.
Table 1.2 Neutron capture cross sections of different elements.
Element Cross section (barns)
B-10

3850

Li-6

940

He-3

5333

N

1.84

H

0.33

C

0.0034

O

0.00018
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The failure of the early BNCT clinical trials were attributed to two aspects: the
inadequate tissue penetration of thermal neutron beams and the insufficient accumulation
of B-10 in the tumors. The Brookhaven clinical trials used a variation of B-10 compounds,
including borax, pentaborate, and boronic acid. These compounds were unable to yield a
high tumor-to-brain ratio, and radiation-induced toxicities were frequently reported.36
Currently, there are two B-10 compounds that have shown to provide improved B-10
accumulation and are used in BNCT clinical trials: p-phenylalanine (BPA) and sulfhydryl
borane (BSH).37,38 BSH could attain a tumor-to-blood ratio between 1.3:1 to 2:1, but it
cannot cross the blood-brain barrier.39,40 As a result, BSH can only deliver boron to the
main tumor mass but not to the infiltrating tumorous cells in the normal brain. In contrast,
BPA is actively transported across the blood-brain barrier. The average BPA concentration
in the tumor is 2-4 times greater than those in the blood and the brain.41-43 BPA was also
found in the region several millimeters away from the main tumor mass, indicating that
BPA was able to reach the infiltrating tumor cells.44,45
The second reason for the poor clinical results was the use of thermal neutron
beams. The superficial layers of tissues effectively attenuate thermal neutrons and absorb
majority of the radiation dose. Thus, thermal neutron beams are more useful for irradiating
melanoma and shallow tumors. After the initial BNCT clinical trials, much effort had
focused on developing higher neutron energy beams to reduce the radiation dose to healthy
tissues and to increase the penetrability of the beam. In the 1990s, reactor-based BNCT
facilities at Brookhaven and MIT made modifications to the reactor to extract the
epithermal neutrons and carried out clinical trials with epithermal neutron beams.46-48 In
these clinical trials, many adverse effects were associated with a temporary increase in
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intracranial pressure. The median survival for the patients was 13 months, comparable to
with resection and standard treatments. These efforts were followed by other international
developments, such as in Petten, Finland, Sweden, and Japan.49-52 The median survival
overall ranged between 13 and 15 months. The study in Japan reported a median survival
of 20.7 months. However, the Japan protocol consisted of intraoperative irradiation. Other
groups have developed accelerator-based facilities and made considerable progress.53,54
The accelerator-based neutron sources are advantageous in certain aspects but still have
yet to reach the same neutron intensity as the nuclear reactors. Further discussion on
neutron sources is presented in Section 1.2.3.
The B-10 compound issue of BNCT is less pressing than the neutron source aspect.
Studies have demonstrated the effectiveness of BPA and BSH in selectively delivering B10 to the tumor cells. For the availability of BNCT neutron sources, however, there remains
technical challenges that need to be overcome to establish a reliable clinical source.
1.2.3

BNCT Neutron Sources

1.2.3.1 Nuclear Reactors
From the first BNCT trials to the early 2000’s, nuclear reactors had been the only
neutron source used for clinical studies. Initially thermal neutrons extracted from the
reactor cores were utilized for clinical work. To improve the tissue penetrability of the
neutron beam, institutions made modifications to their facilities to produce epithermal
beams. There are two approaches to modify a reactor. The first approach is to add
resonance scattering materials to scatter and moderate the fast neutrons in the reactor core
along with filters to remove thermal neutrons and photons of the spectrum. The additional
materials, however, also attenuate the useful neutron beam and reduce the neutron fluence.
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The second approach is to place a fission converter plate adjacent to the moderator
assembly. Reactor-based neutron sources (RBNS) can produce beam characteristics that
approach the optimum for BNCT.51,55 The neutron spectrum of RBNS has an average
energy of 2 MeV and can extend up to 10 MeV. Table 1.3 displays the neutron beam
properties of some of the reactor-based BNCT facilities.
Table 1.3 Neutron beam properties of the earliest nuclear reactor-based BNCT
facilities.56
Reactor

Epithermal

Fast neutron dose per

Photon dose per

power

flux

epithermal fluence

epithermal fluence

(MW)

(109 cm2-s)

(10-13 Gy-cm2)

(10-13 Gy-cm2)

FiR

0.25

1.1

2

0.5

BMRR

3

0.8

5

2

MITR

5

0.2

13

13

HFR

45

0.3

10

8.6

Reactor

Despite that reactors can generate high quality neutron beams and are the only
neutron source that can produce adequate fluence, they have several drawbacks, including
the presence of radioactive materials, low public acceptability, high capital expenses, and
difficulties in modifying the reactor configuration. If alternations to the neutron source are
needed for clinical purposes, it can be complicated and time-consuming for a RBNS.
Nuclear reactors are also dependent on political and economical factors, which have led to
decommission and closure of most of such facilities. Reactors are not meant for clinical
applications and thus, require complicated licensing procedure. These factors have
prevented the installation of reactors in hospital settings. Since construction of new nuclear
reactors is extremely unlikely, there will be a lack of BNCT facilities for treatment in the
future.
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1.2.3.2 Particle Accelerators
Accelerator-based neutron sources (ABNS) have several advantages over RBNS.
First, ABNS can be turned off with no constant radioactivity being produced. ABNS also
has lower capital expenses and are more familiar to clinicians in hospital settings. The most
popular ABNS use proton beams with either a lithium or beryllium target. The
characteristics of the two types of ABNS are shown in Table 1.4. The proton beam requires
between 30 and 80 kW of power. The popular reaction is 7Li(p,n)7Be. With this type of
ABNS, the threshold energy for the impinging protons is 1.88 MeV. Protons are
accelerated up to 2.5 MeV, producing neutron beams with energy between 35 and 573 keV
and an average energy of 233 keV.57 The advantage of this neutron source is that the
neutron energy is very close the epithermal energy range and, thus, requires little
moderation. However, in order to achieve an adequate neutron flux for BNCT of deepseated tumors, it is necessary to increase the Li target thickness and the accelerator current
to tens of mA, and the heat density deposited in the target becomes very high. Due to
lithium’s low thermal conductivity and melting point, target integrity and the risk of target
failure become an issue for p + Li BNCT neutron source. Another issue that arises is the
accumulation of radioactive 7Be from target activation after extended use, which could
cause implications associated to system contamination.58
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Table 1.4 Characteristics of accelerator-based BNCT neutron sources.

Reaction
7

Li(p,n)7Be

9

Be(p,n)9B

Proton
energy
(MeV)

Neutron
production rate
(n/min-mA)

Maximum
neutron
energy (MeV)

1.8959
2.560
2.559
4.059

6.3 x 109
9.3 x 1011
3.9 x 1010
1.0 x 1012

0.067
0.573
0.574
2.12

Target
melting
point
(°C)

Target thermal
conductivity
(W/m-K)

180

85

1287

201

An alternative to 7Li for the target material is 9Be. The 9Be(p,n)9B ABNS is less
common than the 7Li(p,n)7Be type but doesn’t have the target manufacturing issue and
radioactive products. The threshold energy for the reaction is 2.06 MeV. With a
bombarding energy of 2.5 MeV, the maximum neutron energy was 0.57 MeV. However,
to generate the same neutron production as the 7Li(p,n)7Be reaction, the proton energy
would need to increase to 4.0 MeV, which increases the neutron energy as well. As a result,
additional moderator is required to moderate the high-energy neutrons.
While ABNS has the advantage of siting in a hospital and is less expensive than
RBNS, they remain a tremendous financial investment for institutions. In addition, ABNS
usually requires auxiliary equipment that may take up large spaces. Considerable
improvements are still needed to reach the beam intensity and quality of RBNS. The
identification of the effectiveness of BNCT in treatment of GBM is lacking due to the small
patient size and the absence of a clinically appropriate neutron source. It is difficult to make
substantial progress in BNCT without a reliable neutron source for widespread and
accessible use. Compact neutron generators (e.g. deuterium-deuterium) is a competitive
BNCT neutron source that can help with the challenges that BNCT encounters.
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1.3

Deuterium-Deuterium Neutron Generator
A deuterium-deuterium (DD) neutron generator uses deuterium ions to induce

fusion reaction (2D + 2D à n + 3He) and produce neutrons with an energy of 2.45 MeV. It
has been operating in various settings around the world, such as universities, research
institutions, and private industries. The main components of the generator include the
plasma ion source, acceleration chamber, and target (Figure 1.3a). Deuterium is supplied
to the plasma source from a bottle of compressed gas attached to the side of the generator
rack. The gas flows into and is ionized by the plasma source that is powered by
radiofrequency microwave. The deuterium ions are then accelerated toward a negatively
biased titanium target in the acceleration chamber with a negative potential of -100 to -150
kV. As the ions impinge on the target, they implant and form titanium hydrate on the target
surface. When the target surface is saturated with deuterium ions, subsequent ions that
reach the target initiate the fusion reaction, releasing 2.45-MeV neutrons. When the
generator is first started, neutron output will increase with time as the titanium hydrate
begins to form. Once saturation is achieved, neutron output will stabilize. Unlike sealed
sources, the production of neutrons is controlled by bombarding deuterium ions on the
target and not limited by the age of the target. Therefore, the DD neutron generator has a
considerably long life of operation. The most current model of the generator in our lab
(Figure 1.3b) is capable of producing a neutron yield of 2 x 109 n/s.
DD neutron generators offer several advantages over nuclear reactors and large
medical accelerators, including the compact size, competitive cost, ability to turn off
completely, low acceleration voltage, and absence of radioactive materials. With sufficient
effort and development, DD neutron generators may be able to compete with other neutron
sources.
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(a)

(b)

Figure 1.3 (a) Schematic of a deuterium-deuterium neutron generator.61 (b) Picture of the
most current DD neutron generator in our laboratory.
1.4

Monte Carlo N-Particle
Monte Carlo simulation, developed by Los Alamos National Laboratory, is a

particle transport code that performs analytical calculations in 3-D geometry from particle
interactions. It has the capability to simulate transport of photons, neutrons, and electrons
and provides accurate dose calculations and distributions within a geometry. Users can
input the source specifications and phantom configurations to model a radiological
scenario. MCNP tracks the particles and determines the energy deposited by the particles
based on the cross sections of each interaction. With a large number of particles, the MCNP
results accurately predicts the experimental ones. This dissertation work used Monte Carlo
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N-Particle (MCNP) simulations extensively to simulate irradiation design and determine
radiation dose to various tissues.

1.5

Overall Goal and Specific Aims
The overall goal of this dissertation work is to design and optimize a DD neutron

generator-based BNCT system and to examine the dosimetric properties of the neutron
output. The following specific aims will assess the overall objective:
Specific Aim 1: Determine the optimal neutron energy for BNCT of the brain.
The objective of the first aim was to determine the dosimetric effects of monoenergetic
neutrons on healthy tissues as well as brain tumor. This work was done using Monte Carlo
simulations. A monoenergetic neutron source was placed behind a head phantom, and the
doses to the brain, skin, and tumor were evaluated. Neutron energies between 0.5 eV and
2.45 MeV were investigated. Results from this specific aim will provide a baseline from
which to design and compare our DD-based BNCT system.
Specific Aim 2: Design a beam shaping assembly for a DD neutron source. We
designed a beam shaping assembly for a DD neutron generator to moderate and adjust the
neutron spectrum to the desired energy range found in Specific Aim 1. The results of our
proposed BNCT system were compared to those of other BNCT neutron sources and
international recommendations.
Specific Aim 3: Generate BNCT treatment plans in Monte Carlo with the
optimized DD system. BNCT treatment plans were generated using a whole-body
phantom converted from a male cadaver and the optimized DD system from the previous
aim. The beam angle and treatment setup were varied to examine the difference in dose
distributions. Dose-volume histograms were generated for each treatment plan.
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1.6

Innovation and Impact
Current BNCT clinical trials are performed at either a reactor-based or accelerator-

based facility, which is not appropriate for general hospital settings due to the expenses,
size, and architectural complexity. Development in BNCT has been limited by the lack of
a suitable neutron source for clinical studies. The proposed DD-based BNCT system is
compact, less expensive, and relatively easy to install. The advantages of the system
include the reduction in cost of BNCT facilities and increase in access to BNCT for large
patient populations. With an accessible neutron source, extensive BNCT data and
experience can be collected. It is also expected that this research would stimulate interests
in B-10 carrier development and future studies on improvements of present neutron
generator technology. In addition, results from this dissertation research can be applied to
BNCT treatment of other human diseases (e.g. head and neck cancers, hepatocellular
carcinoma).
Few studies have investigated the efficacy of a DD neutron generator for BNCT and
mainly focused on designing a beam shaping assembly and determining the in-air
characteristics of the beam output.62-65 The proposed research is innovative in that dose
distributions within tissues will be examined in detail and a dose-volume histogram will be
generated.

1.7

Structure of Dissertation
The structure of the dissertation is organized by the specific aims. Chapter 1

consists of introduction to the research topic and background on relevant materials.
Chapters 2 to 4 each present one specific aim. Chapter 5 summarizes the overall conclusion
of the dissertation research and future directions.
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CHAPTER 2.
OPTIMAL NEUTRON ENERGY FOR BORON
NEUTRON CAPTURE THERAPY OF THE BRAIN

2.1

Introduction
Early clinical work in BNCT had been performed using thermal neutron beams.

However, thermal neutrons have poor tissue penetration and, as a result, deposit a
substantial amount of dose to the skin and shallow soft tissues and are unable to reach deepseated tumors. Patients from the early clinical trials often exhibited extensive brain necrosis
and skin dermatitis after BNCT treatments.32,39 In the 1990’s, BNCT facilities began to
transition from low-energy thermal neutron beam to higher-energy epithermal neutron
beam to achieve better tissue penetration.47,50,51,66 Although the benefits of epithermal
neutron beams were recognized in clinical trials, the fundamental characteristics of
epithermal neutrons and of an optimal BNCT beam are still not well understood. The goal
of this study was to examine the effects of neutron energy on BNCT of the brain and to
determine the optimal neutron energy that is suitable for treatment of both shallow and
deep-seated brain tumors. The dosimetric properties of monoenergetic neutron beams will
be examined as a function of neutron energy, tumor position, and tissue depth. While other
studies have performed similar work, our study would not only further confirm others’
results but also establish a set of baseline data for designing our own BNCT system and
subsequent research works.67,68
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2.2
2.2.1

Materials and Methods
Monte Carlo N-Particle Simulation
Simulations were performed using MCNPX version 2.7.0. The simulation model

consisted of a neutron source and a male head phantom. The neutron point source was
placed at 3.5 cm from the posterior skin surface of the head phantom and aligned to the
center of the brain. The source emitted monoenergetic neutrons isotropically, and the
neutron energy was varied between 0.5 eV and 2.45 MeV. The head phantom design was
based on the configuration described in the Medical Internal Radiation Dose (Figure 2.1).69
The normal tissues of the head phantom included the brain, skin, cranium, and soft tissues.
Radiation dose was examined in the brain, skin, and tumor. The brain volume was 1402.15
cm3, and the skin volume was 133.21 cm3. Elemental compositions of the tissues were
defined according to the International Commission on Radiation Units and Measurements
(ICRU) Report 46 as shown in Table 2.1.70
Two forms of tumor configuration were used. For average dose calculation, a
spherical tumor with 2.5 cm in radius was placed in the brain along the central beam axis
(Figure 2.2a). The location of the tumor was varied from 5 to 10 cm and defined as the
distance between the posterior skin surface and the center of the tumor. Tumor location of
5 cm was the shallowest position, and the 10-cm location indicated that the tumor was in
the center of the brain, as shown in Figure 2.2a. All doses calculated using this
configuration were averaged over the tumor and normal tissue volumes.
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Cranium

Scalp
Brain

Anterior

Posterior

Soft tissues

Figure 2.1 Modified male head phantom based on MIRD.

Table 2.1 Elemental compositions of the male head phantom.
Element (% weight) Brain

Cranium

Skin Soft Tissue

H

10.7

5.0

10.0

10.5

C

14.5

21.2

20.4

25.6

N

2.2

4.0

4.2

2.7

O

71.2

43.5

64.5

60.2

Na

0.2

0.1

0.2

0.1

P

0.4

8.1

0.1

0.2

S

0.2

0.3

0.2

0.3

Cl

0.3

-

0.3

0.2

K

0.3

-

0.1

0.2

Others

-

0.2 Mg, 17.6 Ca

-

-

� (g/cm3)

1.04

1.61

1.09

1.03
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For maximum doses, a series of tally cylinders were placed along the central beam
axis within the brain starting at 1 cm depth and extending to 17 cm (Figure 2.2b). Each
cylinder was 2 cm in diameter, 0.5 cm in height and had a volume of 1.57 cm3. For skin
dose, a 0.035-cm3 cell was created and placed in the skin at the beam entrance. Due to the
small volumes of the tally cells, the dose calculated in each cell was considered the
maximum dose. Simulations were terminated when statistical uncertainty was within 5%.

(a)

(b)

Figure 2.2 (a) Male head phantom and a spherical tumor with 2.5 cm in radius. (b) Male
head phantom and tally cylinders along the central beam axis.

2.2.2

BNCT Dose Calculations
The total BNCT dose is composed of several radiation components with differing

LET characteristics. In addition to the boron dose deposited by alpha particles and lithium
ions, other principal dose components include neutron and photon doses that are either
inherent in the beam assembly or produced via interactions with normal tissues. Neutron
dose is deposited via recoiled protons and originates from neutron scattering interaction
with hydrogen, 1H(n,n’)p, and capture interaction with nitrogen, 14N(n,p)14C. Photons are
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produced when neutrons interact with the assembly materials around the source as well as
from neutron capture by hydrogens, 1H(n,γ)2H. Each dose component was assumed to act
independently of one another and can be calculated individually. To determine the neutron
and photon doses deposited in a given cell, the neutron and photon fluences were tallied
and modified by their respective fluence-to-dose KERMA factors.71,72 For alpha dose, the
neutron fluence was first modified by the alpha fluence-to-dose KERMA factors and then
by the B-10 concentration in the specific tissue.73 The brain had 15 ppm of B-10
concentration. The skin and the tumor possessed 1.5 and 3.5 times the B-10 concentration
in the brain, respectively. B-10 was assumed to be evenly distributed throughout the
volume. The B-10 concentrations used in MCNP are listed in Table 2.2. The total dose in
air was the sum of all dose components (neutron, photon, and boron) and expressed in unit
of Gray (Gy) or Gy per source neutron.
Table 2.2 Boron-10 concentration, CBE and RBE values for different tissues.
Tumor

Brain

Skin

B-10 concentration (ppm)

52.542

1543,66

22.542,43,66

CBE

3.874

1.375,76

2.577,78

RBEγ/RBEn

1/3.374,79

The biologically weighted total dose in a given tissue was calculated by summing the
weighted dose components, as shown in Equation (1).
�#,% = ���% �* + ���- �- + ���. �.
where
DT,w = the weighted total dose to tissue w
CBEw = the compound biological effectiveness of boron dose for tissue w

(1)
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D� = boron dose
RBEn = the relative biological effectiveness of neutron dose
Dn = neutron dose
RBE� = the relative biological effectiveness of photon dose
D� = photon dose
The unit for the weighted dose is Gray-Equivalent (Gy-Eq) or Gy-Eq per source neutron
to account for the different LET radiation types and relate to photon-equivalent units.
2.2.3

Evaluation Parameters

2.2.3.1 Average Dose Configuration
For average dose calculation using the head phantom with a spherical tumor (Figure
2.2a), the evaluation parameters consisted of the average dose for the brain, skin, and tumor
as well as the dose ratio between the tumor and the brain as a function of neutron energy
and tumor location. The average dose was the dose deposited to a given tissue averaged
over the entire tissue volume.
2.2.3.2 Maximum Dose Configuration
While the average dose provides dose comparison among different tissues, it is not
indicative of how the dose is distributed within a volume. For brain, because of the large
volume of 1402.15 cm3, the dose could be concentrated in one region but still averaged
over the entire volume. Therefore, assessment of maximum dose was considered as well.
For the head phantom with tally cylinders in Figure 2.2b, the evaluation parameters that
were examined incorporate the maximum dose and are commonly used in the BNCT
community: advantage depth and advantage ratio.80 Advantage depth (AD) is the depth in
tissue where the tumor dose is equal to the maximum normal tissue dose. AD represents
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the maximum depth for therapeutic benefits, beyond which the maximum tolerable normal
tissue dose is exceeded. Advantage ratio (AR) is the ratio between the tumor dose and the
normal tissue dose integrated from 1 cm depth to the AD. AR indicates the ability of the
neutron beam to minimize dose to normal tissues. BNCT clinical studies have that brain
was the dose-limiting tissue in BNCT irradiations. Thus, the maximum brain dose of 12.5
Gy-Eq was used to determine AD and AR in the study.81,82 AR and AD were evaluated as
a function of neutron energy and depth.

2.3
2.3.1

Results
Average Dose

2.3.1.1 Tumor Dose
Figure 2.3 shows the total tumor dose per source neutron as a function of neutron
energy for different tumor locations. All tumor locations had similar dose trends with
neutron energy: the average tumor dose stayed relatively constant before 100 keV and
increased substantially when the neutron energy increased from 100 keV to 2.45 MeV. The
shallow tumors overall received more dose per source neutron, and the effect of neutron
energy was less notable on the deep-seated tumors.
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Figure 2.3 Total average dose to the tumor as a function of neutron source energy.

Figure 2.4 Neutron dose contribution to the total average tumor dose as a function of
neutron source energy.
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Figures 2.4 to 2.6 display the individual dose components in dose per source
neutron of the total tumor dose in Figure 2.3. Figure 2.4 represents the neutron dose
contribution as a function of neutron energy for all tumor locations. Neutron contribution
was more prominent in shallow than deep tumors as well as when the neutron energy was
above 10 keV. When the neutron energy was in the epithermal range or less, the dose
contribution from neutrons didn’t vary greatly. At energy greater than the epithermal,
neutron dose increased rapidly with energy. In addition, at those high neutron energies, the
largest dose contribution out of all dose components was neutron. Figure 2.5 shows the
dose contribution from alpha. Overall, shallow tumors received more alpha dose than deep
tumors. For shallow tumors, the alpha dose contribution was at maximum when the neutron
energy was at 5 eV for tumor locations of 5 and 6 cm, and at 1 keV for 7 cm. As the tumor
location increased, the neutron energy that had the maximum alpha dose increased as well
to 100 keV for tumor locations of 8 and 9 cm, and to 1 MeV for tumor location of 10 cm.
When the neutron energy was below 100 keV, the alpha dose component was greater than
the neutron component for all tumor locations. When the neutron energy was in the MeV
range, the alpha dose contribution became less significant.
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Figure 2.5 Alpha dose contribution to the total average tumor dose as a function of
neutron source energy.

Figure 2.6 shows the photon dose component of the total dose as a function of
neutron energy for all the tumor locations. In contrast to the alpha and neutron doses, the
photon dose contribution stayed relatively constant with neutron energy and tumor depth.
In general, the photon dose contribution decreased with increasing neutron energy, and
shallow tumors received more photon dose than deep tumors. At high neutron energies, the
tumor obtained the same dose relatively, regardless of the tumor location. When the tumor
was situated in the middle of the brain, neutron energy had a modest effect on the dose.
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Figure 2.6 Photon dose contribution to the total average tumor dose as a function of
neutron source energy.

The fraction of contribution from the individual dose components to the total tumor
dose as a function of neutron energy is shown in Figure 2.7. For each dose component, the
fraction was calculated by averaging the fractions at each neutron energy over all tumor
locations. Alpha contribution was the largest of all dose components (between 0.7 and 0.8)
when the neutron energy was less than 100 keV and dropped off rapidly when the energy
increased to the MeV range. The neutron dose fraction was minimized at neutron energies
below 100 keV and increased to greater than 0.9 at 2.45 MeV. The photon fraction stayed
at less than 0.2 for most of the neutron energies and decreased further at 1 and 2.45 MeV.
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Figure 2.7 The averaged dose fraction of the total tumor dose that originated from the
individual dose components.

Figure 2.8 compares the average tumor dose and the dose components between
neutron energy of (A) 10 keV and (B) 2.45 MeV. Although a 10-keV neutron beam
delivered less dose per neutron source than a 2.45-MeV neutron beam, the total dose
largely came from alpha particles, and the neutron dose contribution was the smallest. On
the contrary, when the neutron energy was increased to 2.45 MeV, neutron accounted for
almost all of the total dose, and alpha and photon dose fractions were substantially smaller.
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(A)

(B)

Figure 2.8 The total tumor dose and the individual dose components as a function of
depth for two neutron energies. (A) 10 keV and (B) 2.45 MeV.
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2.3.1.2 Brain Dose
Figure 2.9 displays the total average dose to the brain as a function of neutron
energy for all tumor locations. The total dose had subtle changes at low neutron energies.
It increased and then decreased slightly with increasing energy. The lowest dose occurred
at 1 keV, above which the total dose started to increase and then exponentially after 10
keV. The brain dose was not affected substantially by the tumor location. Figures 2.10 to
2.12 represent the neutron, photon, and alpha dose fractions of the total dose, respectively.
The neutron contribution in Figure 2.10 exhibited similar trend as the total dose, where the
dose showed gradual variations with energy when the neutron energy was less than 10 keV
and increased exponentially at higher neutron energies.

Figure 2.9 Total average dose to the brain as a function of neutron source energy.
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Figure 2.10 Neutron dose contribution to the total average brain dose as a function of
neutron source energy.

The photon dose component is shown in Figure 2.11 as a function of neutron energy.
The photon dose was greater with lower neutron energies and deeper tumor locations. Dose
variation with neutron energy was less apparent than the neutron component. Figure 2.12
demonstrates the alpha dose component of the total brain dose. With higher neutron
energies and shallow tumor locations, the brain obtained less alpha dose. When the neutron
energy was in the eV range, the alpha dose in the brain was maximized.
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Figure 2.11 Photon dose contribution to the total average brain dose as a function of
neutron source energy.

Figure 2.12 Alpha dose contribution to the total average brain dose as a function of
neutron source energy.

33
The fraction of the total brain dose that originated from the individual dose
components is shown in Figure 2.13. The dose fraction at a given neutron energy was the
average of all fractions at the same tumor location. For neutron energies below 10 keV,
photon dose was the largest contributor to the total brain dose, followed by alpha then
neutron. The photon fraction was around 0.5 before declining to 0 with increasing neutron
energy. The alpha dose fraction was between 0.25 and 0.3 in the epithermal energy range
and, like the photon fraction, decreased to 0 with increasing neutron energy. When the
neutron energy was above 10 keV, the neutron dose component increased exponentially
and was responsible for nearly the entire total dose at 1 and 2.45 MeV.

Figure 2.13 The averaged dose fraction of the total brain dose that originated from the
individual dose components.
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Figure 2.14 compares the average brain dose and the dose components between two
distinct neutron energies: (A) 10 keV and (B) 2.45 MeV. Each figure represents the total
dos deposited per source neutron as a function of tumor depth. When the neutron energy
was in the epithermal range (10 keV), the brain received less dose per source neutron, and
photon was the largest dose contributor while neutron was the lowest. When the neutron
energy was at 2.45 MeV, the total brain dose was more than 30 times the dose with 10-keV
neutrons, and the individual neutron dose was nearly the same as the total dose, indicating
that the brain dose largely originated from the neutron beam.
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(A)

(B)

Figure 2.14 The total brain dose and the individual dose components as a function of
depth for two neutron energies. (A) 10 keV and (B) 2.45 MeV.
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2.3.1.3 Dose Ratio
The dose ratio between the tumor and the brain as a function of neutron energy for
all tumor locations is displayed in Figure 2.15. Deep-seated tumors overall had lower dose
ratios than shallow tumors. The 5-cm tumor location had the largest dose ratio at all neutron
energies, ranging between 13 and 17 in the epithermal range and between 4 and 13 in the
fast energy range. For all tumor locations, the dose ratio initially increased with neutron
energy and, after reaching a maximum value in the keV range, began to drop. The decrease
was more noticeable when the neutron energy transitioned from epithermal to fast. As the
tumor got deeper, the difference in dose ratio between epithermal and fast neutrons was
less apparent. For the 10-cm tumor location, epithermal neutrons obtained dose ratios
between 1 and 3 while fast neutrons’ were between 0 and 3. When the tumor was at 9 and
10 cm depth, the dose ratio with high energy neutrons was close to 1, illustrating that the
tumor and the brain received comparable amount of dose.
Table 2.3 lists the neutron energy with the highest dose ratio and their values for all
tumor depths. When the tumor was at a shallow location of 5 cm, 5-eV neutrons had the
largest dose ratio between the tumor and the brain. As the tumor location continued to
increase to the middle of the brain, neutron energies with the highest dose ratio values rose
to 1 keV and 8 keV. Overall, the highest dose ratio occurred when the neutron energy was
between 5 eV and 8 keV.
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Figure 2.15 Dose ratio between the tumor and the brain as a function of neutron energy
for all tumor locations.

Table 2.3 The dose ratio and the optimal neutron energy for BNCT of different tumor
locations.
Tumor location (cm)

5

6

7

8

9

10

Dose ratio

16.8

11.5

7.9

5.4

3.7

2.5

Optimal neutron energy (MeV) 5E-6 1E-3 1E-3 1E-3 8E-3 8E-3

2.3.1.4 Skin Dose
The total average skin dose and its individual dose components as a function of
neutron energy are displayed in Figure 2.16. Different from the tumor and the brain dose,
the skin dose per source neutron was not affected by the tumor location if the neutron
energy remained unchanged. The total skin dose first decreased when the neutron energy
went from 0.5 eV to 1 keV, then increased quickly above the initial dose with increasing
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neutron energy. Alpha dose was the largest dose component before 1 keV, followed by
photon and neutron. Alpha and photon doses continued to decrease to increasing neutron
energy while the trend for the neutron component was reversed. At 1 keV, the three dose
components reached a crossover point and contributed similar amount of dose, and the
neutron fraction increased exponentially. At above 100 keV of neutron energy, almost the
entire skin dose came from neutrons.

Figure 2.16 The total average skin dose and the individual dose components as a function
of neutron source energy.

2.3.2

Maximum Dose

2.3.2.1 Advantage Depth and Advantage Ratio
Figure 2.17 shows the AD and AR data as a function of neutron energy. AD started
at 5.24 at 0.1 eV, increased with neutron energy, and reached a maximum value of 9.26 at
2 keV. At neutron energies beyond 10 keV, AD started to decrease rapidly with increasing
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energy and leveled out at 100 keV. The minimum value was 1.5. For AR, the value began
at 5.48 at 0.1 eV and stayed relatively constant with energy until 8 keV. Similar to the trend
in AD, AR declined with increasing energy beyond 8 keV and began to plateau at 100 keV.
At neutron energies of 1 and 2.45 MeV, the AR had the minimum value of 1, or the brain
and tumor tissues received the same dose.

Figure 2.17 The Advantage depth and advantage ratio as a function of neutron energy.

Figure 2.18 shows the maximum skin dose per source neutron and the normalized
maximum skin dose as a function of neutron energy. The maximum dose per source
neutron started low at 0.1 eV and decreased further with increasing neutron energy. The
minimum occurred at 100 eV, however, beyond which the dose began to escalate. The
increase was more rapid after 10 keV. The normalized dose curve was calculated based on
and normalized to the maximum brain dose. Comparable to the curve for the dose per
source neutron, the normalized dose first decreased with neutron energy until it reached
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100 eV and began to increase after. At 25 keV, the normalized dose reached a maximum
dose of 1.7 Gy-Eq and decreased again at higher neutron energies. The maximum skin dose
was well within the reported tolerable dose, regardless of the neutron source energy.

Figure 2.18 Maximum skin dose as a function of neutron energy.

2.3.2.2 Dose Profile
The dose profiles for the tumor and the brain are shown in Figure 2.19 for neutron
energy (A) 0.1 eV, (B) 2 keV, and (C) 2.45 MeV. The dose on the y-axis was normalized
to the maximum tolerable brain dose of 12.5 Gy-Eq. When the neutron energy was 0.1 eV,
the total dose to the tumor and the brain both decreased with increasing depth. The tumor
received significantly more dose than the brain, and the alpha component made up the
largest fraction of the total tumor dose while the neutron contribution was minimal. With
2-keV neutrons, the total tumor dose was less than that with 0.1-eV neutrons. The tumor
exhibited a buildup region between 1 and 3 cm depths and acquired more dose than the
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brain. The alpha component composed the largest fraction of the total tumor dose while
neutrons remained the smallest dose contributor. The brain dose profile also did not
decrease as fast as when the neutron energy was 0.1 eV. When the neutron energy was
equivalent to those of a DD neutron generator (Figure 2.19c), the doses to the tumor and
the brain were essentially the same. The total doses decreased with depth, and the buildup
region seen in Figure 2.19b was eliminated. Alpha dose contribution was minimized, and
neutrons made up the largest fraction of the total dose.

(A)

Figure 2.19 Dose profiles for the tumor, the brain, and the dose components as a
function of depth for neutron energies of (A) 0.1 eV, (B) 2 keV, and (C) 2.45 MeV.
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Figure 2.19 continued
(B)

(C)
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2.4

Discussion and Conclusion
The purpose of the study was to examine the effect of neutron source energy on the

dose deposited to different tissues and to determine the optimal neutron energy for BNCT
for brain tumors. When the neutron energy was between 0.5 eV and 10 keV, the alpha dose
component accounted for nearly 80% of the total tumor dose for all tumor locations. On
the contrary, at 1 and 2.45 MeV, neutrons were the main contributor to the tumor dose.
While the higher neutron energies were more efficient in delivering dose to the tumor in
terms of dose deposited per source neutron, a large fraction of the delivered dose emerged
from the inherent neutron beam. Epithermal neutrons deposited less dose per source
neutron to the tumor; however, they produced the largest alpha dose fraction for all tumor
locations. With an epithermal neutron beam, more neutrons were thermalized by the
normal tissues when they reach the tumor site as compared to a thermal neutron beam,
generating more alpha particles and lithium ions at the tumor site. The thickness of the
brain tissue was insufficient to effectively moderate higher energy neutrons, or fast
neutrons. As a result, the alpha contribution to the total tumor dose and the therapeutic
advantage of BNCT were diminished.
The average brain dose stayed relatively constant with tumor location compared to
the tumor dose. As the tumor moved deeper in the brain, more brain tissue was exposed to
the neutron beam and thus, received more dose. In the epithermal energy range, photon
was the largest dose contributor while neutron was the least. When the energy was
increased further, the total dose increased exponentially, and the neutron dose exceeded
the photon and alpha components. At 1 and 2.45 MeV, neutron was responsible for more
than 90% of the total brain dose. In BNCT, in addition to maximizing the production of the
high LET particles inside the tumor, it is also important to keep the risk of radiation
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toxicities in the brain to as low as possible. Results demonstrated that epithermal neutrons
reduced the dose deposited by neutrons to the brain while allowing the maximal nuclear
interaction between thermal neutrons and B-10. Fast neutrons (> 10 keV) delivered
significantly more dose to the tumor as well as to the brain, as evident in the dose ratio in
Figure 2.15. The dose ratio was the highest in the epithermal range and was drastically
reduced as the neutron energy increased, especially at 1 MeV and 2.45 MeV, indicating
that the high-energy neutrons were depositing just as much dose in the brain as in the tumor.
The average and maximum skin dose per source neutron decreased when the
neutron energy went from the thermal to the epithermal range and then increased
substantially at the higher energies. Due to the lower neutron capture cross section for
epithermal neutrons, the skin obtained less dose than when the neutron source energy was
thermal. However, this benefit was offset at higher energy likely by the neutron scattering
interaction with hydrogens, causing the dose to escalate again. The normalized maximum
skin dose did not display the same trend as the average and maximum doses because it was
calculated based on and fluctuated with the maximum brain dose and the amount of
neutrons required to reach the brain tolerance. At high neutron energies, the maximum skin
dose decreased because the brain tolerance was reached with fewer number of source
neutrons. Therefore, the irradiation time was reduced and so was the skin dose. There has
not been a consensus about the skin tolerance dose among literature. The dose ranges from
11 to 18 Gy-Eq.77,78 However, the maximum skin dose in the results was well below any
of the reported tolerance dose and was not the dose-limiting factor in BNCT.
While the average dose provided comparison in doses in different tissues, it was
not an accurate representation of the dose distribution within a tissue. For example, the
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brain encompasses a large volume, and the dose may have concentrated in the region
closest to the neutron source but was averaged over the whole brain volume. AD and AR
are two figures of merit that are commonly used in the BNCT community and integrate the
maximum brain dose into evaluation. Unlike conventional radiotherapy where the tumor is
prescribed a therapeutic dose, BNCT treatment, and thus the tumor dose, is dependent on
the brain tolerance dose, or 12.5 Gy-Eq. AD and AR examine the quality of the neutron
source by incorporating the brain tolerance dose and determining the conditions in which
the brain dose would be exceeded. The simulation results showed that epithermal neutrons
would optimize both AD and AR, allowing treatment of deep-seated tumors and less dose
delivery to the normal tissues. At high neutron energies, the AR was close to 1, indicating
that the integrated doses to the tumor and the brain were essentially equal.
The dose evaluation in this study did not consider the cranium. However, clinical
trials have not reported any adverse effect in the cranium in BNCT. If necessary, the
cranium could be incorporated into the calculation by using the appropriate B-10
concentration and CBE value for the cranium. Studies have found that the B-10
concentration in bone is similar to that in soft tissues and have used a CBE value of 1.2 for
bone dose calculation.83,84 In this study, only the posterior-anterior (PA) beam was
examined. It would be beneficial to expand the study to include other beam orientations,
such as lateral (LAL) and anterior-posterior (AP). The main distinction among the different
beam angles is the radiation exposure to other normal tissues. The brain tends to receive
more dose with a PA beam while more organs (e.g. lens) are exposed to the beam with a
LAL or an AP beam.85,86
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In this MCNP simulation study, epithermal neutrons between 0.5 eV and 10 keV
were found to be the optimal energy range for BNCT of the brain. Since tumor mass will
extend several millimeters within the brain tissue, the range of neutrons will enable
adequate dose coverage at different depths. The simulation results demonstrated that
epithermal neutrons maximized the radiological advantages of using the high LET particles
for the delivery of a therapeutic dose to the target. In terms of average dose, the alpha dose
contribution to the tumor was the greatest when the neutron source was in the epithermal
energy range and the lowest at high neutron energies. For the brain, the neutron dose had
the minimal contribution at epithermal energies but accounted for a significant fraction of
the total brain dose when the neutron energy was in the MeV range. With respect to the
maximum brain dose, AD and AR were found to have the highest values when the source
energy was between 0.5 eV and 10 keV. In addition, the skin dose was reduced with an
epithermal neutron source. In conclusion, epithermal neutrons between 0.5 eV and 10 keV
are optimal for BNCT of brain tumors.
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CHAPTER 3.

3.1

DESIGN OF BEAM SHAPING ASSEMBLY

Introduction
At present, the BNCT neutron sources are limited to nuclear reactors and large

particle accelerators, which are costly to construct and maintain and cannot be widely
incorporated into clinical settings. Due to the lack of a clinically appropriate neutron source,
progress and involvement in BNCT research have been deficient. As an alternative,
compact DD neutron generators possess the financial advantage and convenience over the
conventional neutron sources. In the previous chapter, it was demonstrated that neutrons
in the epithermal energy range between 0.5 eV and 10 keV were optimal for BNCT of brain
tumors at depth between 5 and 10 cm. Epithermal neutrons are able to penetrate deeply
into the brain tissues and are thermalized when they reach the tumor site. As the energy of
DD neutrons is 2.45 MeV, a beam shaping assembly (BSA) is necessary to moderate the
DD neutrons down to the desired epithermal range. In addition to moderation, the purpose
of the BSA also entails removing any background radiation that adds dose to healthy tissues
and doesn’t have any therapeutic benefits. The background radiation includes the fast and
thermal neutrons inherent in the neutron beam as well as photons that are produced from
neutron interactions with the BSA. An optimized BSA should maximize epithermal
neutron output and reduce any unwanted radiation. The goal of this study was to design a
BSA for a DD neutron source to moderate the fast DD neutrons and limit any
contamination radiation in the neutron beam output.
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3.2
3.2.1

Materials and Methods
Monte Carlo N-Particle Simulation
Simulations were performed using MCNPX version 2.7.0. The simulation model

consisted of the MIRD head phantom, a neutron source, and a beam shaping assembly. The
head phantom was the same as the one described in Section 2.2.1 with the tally cylinders
along the central beam axis (Figure 2.2b). There were 32 tally cylinders in the brain and 1
in the scalp. The neutron source was configured based on the most current DD neutron
generator in our lab, manufactured by Adelphi Technology Incorporated. The DD
generator has a titanium target in size of 2 by 2 by 0.2 cm3. When the fusion reaction occurs
at the target, the resulting 2.45-MeV neutrons are evenly distributed over the target and
emitted isotropically. Due to these features of the DD generator, the modeled neutron
source in MCNP was characterized as a 2.45-MeV planar source, enclosed in an aluminum
vacuum casing. It was position behind the head phantom, aligned with the center of the
brain. The exact distance between the source and the phantom varied, depending on the
design of the BSA. The BSA was placed between the head phantom and the neutron source
and was comprised of several components: a moderator, reflector, collimator, and thermal
filter. A schematic of a BSA layout is shown in Figure 3.1. In the simulations, 2.45-MeV
neutrons started at the source and entered the BSA with monoenergetic neutron distribution
until they reached the exit window where the head phantom was located. The BSA
surrounded the neutron source to modulate the neutron energy and shape the spectrum to
the desired energy range. Different materials, geometries, and combinations were
examined for each BSA component to optimize the final neutron output. Some of the BSA
components were determined separately, meaning that different materials were tested for
the component while the other BSA elements stayed constant, but those elements were not
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necessarily the same as the final optimized layout. Simulations were terminated when
statistical uncertainty was within 5%.

Reflector

Neutron
source

Moderator

Collimator

Thermal filter

Neutron beam

Figure 3.1 Schematic of the beam shaping assembly components and layout.

3.2.2

Beam Evaluation

3.2.2.1 In-Air Figures of Merit
After the 2.45-MeV DD neutrons went through the BSA, the resulting neutron
beam was evaluated in two ways: in air and in phantom. The in-air figures of merit (FOM)
were determined at the beam exit window in air before the beam entered the head phantom.
The parameters included the epithermal neutron flux (φepi), the thermal-to-epithermal
neutron ratio (φth/φepi), the fast neutron dose per epithermal (Df/nepi), and the photon dose
per epithermal (Dγ/nepi). Table 3.1 lists the FOMs and the recommended values proposed
by the International Atomic Energy Agency (IAEA).87 The goal was to find the BSA layout
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that would maximize the epithermal neutron flux while adhering to the recommended
values for the other three FOMs or keeping them to as low as possible.
Table 3.1 The in-air figures of merit used for BSA optimization and the recommended
values by the International Atomic Energy Agency.
In-Air Parameters

Recommendations87

Thermal neutron energy

< 0.1 eV

Epithermal neutron energy

0.5 eV to 10 keV

Fast neutron energy

> 10 keV

φepi (nepi/cm2-s)

> 1E9

φth/φepi

< 0.05
2

< 2E-13

2

< 2E-13

Df/φepi (Gy-cm /nepi)
Dγ/φepi (Gy-cm /nepi)

3.2.2.2 In-Phantom Figures of Merit
The in-phantom FOMs were assessed in the brain and skin tally cylinders.
Additional to the AD and AR parameters mentioned in Section 2.2.3.2, the in-phantom
FOMs also consisted of the Advantage Depth Dose Rate (ADDR), peak skin dose, and the
required neutron flux. ADDR is the dose rate at the advantage depth and closely related to
the treatment time. The BSA was optimized to maximize the AD, AR, and ADDR. The
peak skin dose was also determined and compared to the maximum tolerable skin dose in
literature.77,78 The required neutron flux is the flux that is needed to reach the brain
tolerance dose within one hour and was calculated as a reference for future technology
development. The ADDR and the required neutron flux were calculated based on the
neutron flux of our most current DD neutron generator, 5 x 109 n/s.
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3.3
3.3.1

Results
Thermal Filter
The thermal filter is the last component before the neutron beam exited the BSA

completely and was placed immediately before the exit window. The purpose of the filter
was to remove the thermal neutron component from the neutron spectrum since they have
poor tissue penetration and cannot reach deep-seated tumors, depositing radiation dose to
the skin and the normal tissues. The determination of the optimal material for the thermal
filter was relatively straightforward. Figures 3.1 to 3.3 represent the capture cross sections
for cadmium(Cd)-113, lithium-6, and gold(Au)-197, respectively. By examining the cross
section for neutron capture interaction of different materials, Cd was found to be the ideal
material for the thermal filter due to its substantially greater cross section at thermal energy.
The cross section for Cd-113 is around 104 barns whiles it is 102 and 10-2 for Au-197 and
Li-6, respectively. Au-197 had a high thermal capture cross section. However, after
undergoing neutron capture reaction, a high-energy prompt gamma is released, increasing
the photon dose to normal tissues.
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Figure 3.2 Radiative capture cross sections for cadmium-113 from data library END/BVIII.0.

Figure 3.3 Radiative capture cross section for lithium-6 from data library END/B-VIII.0.
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Figure 3.4 Radiative capture cross section for gold-197 from data library END/B-VIII.0.

Cd was highly effective in removing thermal neutrons from the beam output. Thus,
the smallest thickness of Cd that was just enough to reduce thermal neutrons without
perturbing the epithermal neutron fluence was determined. Figure 3.5 displays the
epithermal neutron fluence per source neutron and the thermal-to-epithermal neutron ratio
as a function of Cd thickness. As the Cd thickness increased, the ratio decreased
substantially because more thermal neutrons were removed from the beam. Thicker Cd
filter diminished the epithermal fluence as well but not as significantly. A thickness of 0.02
cm of Cd was found to be the optimal thermal filter because it effectively reduced the
thermal-to-epithermal neutron ratio to well below the IAEA recommendation without
influencing the epithermal flux drastically.
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Figure 3.5 Epithermal neutron fluence per source neutron and thermal-to-epithermal
neutron ratio as a function of Cd filter thickness.

3.3.2

Reflector
Due to the isotropic feature of the DD neutron source, a reflector is necessary to

direct the neutrons toward the beam opening and to maximize the neutron flux in the
forward direction. The reflector is the outermost component of the BSA and surrounds the
neutron source as well as the other BSA components. Some of the materials that were
considered for the reflector component of the BSA included bismuth, polyethylene, lead
(Pb), and iron. With other BSA components remained constant, Pb was found to be the
most effective material for the reflector. Figure 3.6 presents the epithermal neutron fluence
per source neutron at the beam exist window as a function of reflector thickness for
materials Pb and polyethylene. Both materials showed an increase in the epithermal fluence
as the reflector thickness increased. However, Pb had a higher epithermal neutron flux than
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polyethylene for all thickness and exhibited a larger increase in flux with thickness. The
epithermal flux saturated at 8 cm of polyethylene but continued increasing at above 50 cm
of Pb. The increase in flux with Pb reflector eventually began to slow down. While thicker
reflector resulted in better epithermal flux, the amount of applicable Pb to the BSA system
is limited by cost, exposure to the toxic metal, and the load limitation of the floor. As a
result, a thickness of 30cm was decided for the reflector.

Figure 3.6 Epithermal neutron fluence as a function of reflector thickness for materials,
lead and polyethylene.

3.3.3

Collimator
The collimator is located near the end of the BSA, right before the thermal filter.

The purpose of the collimator was to limit the radiation field to the size of the target volume
and to reduce radiation exposure to healthy tissues, without distorting the moderated
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neutron beam. The collimator has similar functions as the reflector and, thus, similar
materials were investigated for the collimator. The final collimator was 10-cm long of Pb
and created a beam aperture of 12 by 12 cm2.
3.3.4

Moderators
The moderator of the BSA component was responsible for moderating the DD

neutrons from fast to epithermal energy and was placed immediately in front of the neutron
source in the beam direction. Compared to other BSA components, the determination of
the optimal moderator materials was more complicated and involved more trial-and-error.
Table 3.2 lists some of the different materials and combinations that were examined for the
moderator as well as the in-air parameters for each.
Table 3.2 In-air parameters for different moderator materials and combinations.
Materials

φepi
5

2

φth/φepi

Df/φepi

Dγ/φepi

(10-13

(10-13

Gy-cm2/nepi)

Gy-cm2/nepi)

(cm)

(10 nepi/cm -s)

AlF3 (50)

1.8

0.01

14

1.8

Li7F (50)

1.5

0.04

6.6

1.8

Li F (45) + MgF2 (10)

1.0

0.05

5.5

2.4

Li7F (45) + AlF3 (10)

1.2

0.04

5.6

3.4

AlF3 (55) + MgF2 (10)

83

0.03

5.4

2.3

MgF2 (60)

80

0.05

6.4

2.7

CaF2 (50)

1.5

0.01

39

2.2

7

3.3.5

Final Beam Shaping Assembly
Figure 3.7 displays the cross-sectional view of the final optimized BSA layout. The

reflector was 30 cm of lead; the moderators included 45 cm of Li7F and 10 cm of MgF2;
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the thermal filter was 0.02 cm of cadmium, and the collimator was 10 cm of lead. The
collimator confined the radiation field to 12 x 12 cm2 to reduce radiation exposure to
healthy tissues.

MgF2

Neutron beam

Neutron source

Li7F

Reflector

Thermal filter

Collimator
Moderators

Neutron source casing

Figure 3.7 Cross-sectional view of the optimized BSA layout.

3.3.5.1 In-Air Figures of Merit
The neutron spectrum at the beam exist window is shown in Figure 3.8 in
epithermal neutron fluence per source neutron. The spectrum presented a peak in the
epithermal energy range with limited thermal and fast neutrons. Table 3.3 shows the in-air
FOMs of the neutron spectrum as well as the IAEA recommendations and data from
existing BNCT facilities.87 The epithermal neutron flux of the optimized BSA system was
1.95 x 10-5 nepi/cm2 per neutron source or 9.4 x 104 nepi/cm2-s. The flux was calculated
based on 5 x 109 n/s, the neutron flux of our most current DD neutron generator. An
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increase of four orders of magnitude was needed to meet the IAEA recommendation. The
thermal-to-epithermal neutron ratio was 0.03 and in agreement with the recommended
value. The fast neutron and photon doses per epithermal neutron were 5.9 x 10-13 and 2.1 x
10-13 Gy-cm2/nepi, respectively. While they exceeded the IAEA criteria, they were within
the range of existing BNCT facilities that are used for treating BNCT patients. In order to
meet the IAEA epithermal neutron flux criterion, the DD neutron flux would need to
increase to 5.1 x 1013 n/s.

Figure 3.8 Neutron spectrum in air at the BSA exit window

Table 3.3 In-air parameter results for the optimized BSA layout as well as the
recommendation by the IAEA and data from existing BNCT facilities.
Proposed System

IAEA87

Existing Facilities87

φepi (nepi/cm2-s)

9.4 x 104

> 1 x 109

φth/φepi

0.03

< 0.05

Df/φepi (Gy-cm2/nepi)

5.9 x 10-13

< 2 x 10-13

2.5 – 13 x 10-13

Dγ/φepi (Gy-cm2/nepi)

2.1 x 10-13

< 2 x 10-13

1 – 13 x 10-13
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3.3.5.2 In-Phantom Figures of Merit
Table 3.4 shows the in-phantom results and the desired DD neutron flux for the
optimized layout. The AD was 12.5 cm, and the AR was 4.4. The ADDR was 2.9 x 10-3
cGy-Eq/min. The DD neutron flux required to perform a BNCT treatment within one hour
was 3.6 x 1013 n/s. If the desired neutron flux was achieved, the ADDR would increase to
20.8 cGy-Eq/min. The peak skin dose was 0.59 Gy-Eq.
Table 3.4 In-phantom parameter results for the optimized BSA layout.
AD (cm) AR

ADDR

DD neutron flux (n/s) Peak skin dose

(cGy-Eq/min)
12.5

4.4 2.9 x 10-3 (20.8)

(Gy-Eq)
3.6 x 1013

0.59

The dose profile for the neutron beam output of the optimized BSA is shown is
Figure 3.9. The figure included the dose profiles for the tumor and the brain as well as the
individual dose components. The dose was normalized to the tolerable brain dose of 12.5
Gy-Eq. The brain dose was the highest near the surface at 1.5 cm depth and continued to
decrease with depth. Neutron was the main dose contributor to the brain, followed by alpha
then photon. The tumor dose was about two to four times greater than the brain dose,
depending on the depth. Contrary to the brain, the tumor exhibited a buildup region in the
dose profile and reached a maximum dose of 47.9 Gy-Eq at 3 cm deep. Alpha dose
accounted for majority of the total tumor dose.
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Figure 3.9 Dose profile of the optimized neutron beam.
3.4

Discussion and Conclusion
The objective of this study was to optimize the BSA layout for a DD neutron source

to moderate the 2.45-MeV neutrons to the epithermal energy range. The final BSA
configuration produced satisfactory in-air and in-phantom results. The epithermal neutron
flux at the beam exist window was 9.4 x 104 nepi/cm2-s, about four orders of magnitude less
than the IAEA recommendation. φth/φepi was 0.03, in agreement with the IAEA; Df/nepi and
Dγ/nepi were greater than the IAEA criteria but comparable to those of existing BNCT
facilities. For the in-phantom FOMs, the IAEA does not have any recommended values.
Thus, our results were compared with those from literature. Table 3.5 shows the inphantom parameters for the proposed DD system and other BNCT facilities with different
neutron sources. MIT and THOR are reactor-based; Yanch et al and Birmingham are
accelerator-based, and Han et al is DD-based. The ADDR and the irradiation time for our

61
system in the table were calculated as if the DD neutron flux was adequate for treatment.
The AD and AR of our beam were comparable to other neutron sources. The ADDR and
the irradiation time were lower than the reactor-based facilities but greater than the
accelerator- and DD-based sources. Reactor-based BNCT systems had comparable AD and
AR to other neutron sources but outperformed in ADDR and treatment time. This may
largely be due to the greater neutron flux that reactors are able to produce. Acceleratorbased facilities had varying results. Yanch et al. had lower AD but higher dose rate and
could complete irradiation in 32 minutes. The Birmingham accelerator beam had better
penetration (higher AD) but much longer treatment time. To our knowledge, Han et al. is
the only study that included in-phantom FOMs for evaluation of a DD-based BNCT system.
Despite their assumption of 1 x 1011 n/cm2-s for the neutron flux, the treatment time was
unpractically long while our DD-based system had a more reasonable irradiation time. The
variations among the facilities could be attributed to the types of neutron source. In addition,
the dose calculation factors and simulation models (e.g. source position and beam aperture
size) used could also contribute to the differences. For example, Yanch et al. applied a 10:1
boron ratio between the tumor and the brain and biological factors of 1, 1.6, and 2.3 for
photon, neutron, and alpha, respectively. The THOR design used a 3.6:1 ratio, and the
biological factors were 1, 3.2, and 1.3 for photon, neutron, and alpha, respectively. These
discrepancies could affect the dose calculations considerably. Although the ADDR and the
irradiation time of our system were based on the assumption that the DD neutron flux was
sufficient for treatment, the in-air FOMs, the AD and the AR demonstrated that the
optimized neutron beam possessed the appropriate dosimetric properties for BNCT of the
brain.
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Table 3.5 Comparison of the in-phantom FOMs and the irradiation time with different
types of BNCT sources.
AD (cm) AR ADDR (cGy/min) Irradiation time (min)
MIT FCB88

9.7

5.7

170

7

8.9

5.6

50

25

Yanch et al

8.5

4.1

7.9

32

Birmingham91

10.3

5.6

5.5

220

Han et al92

9.1

5.6

9.9

822

Proposed system

12.5

4.4

20.8

60

THOR

89
90

The most difficult IAEA recommendations to satisfy were the epithermal flux and
the fast neutron dose. While thicker moderators and filter could further suppress the fast
neutron and photon doses, the epithermal neutron flux would suffer as well. Thinner
moderator would increase not only the epithermal flux but also the neutron and photon
doses, inevitably. Therefore, the trade-off between the epithermal flux and the
contamination radiation doses needed to be balanced. The final moderator combination
was chosen due to its acceptable in-air FOMs and balance between the epithermal fluence
and the fast neutron dose. While our results did not satisfy the IAEA commendations, it is
important to note that the FOMs of our system agreed with those of existing BNCT
facilities.
The materials investigated for the moderator component were largely based on
literature search.62,64,67,93,94 The approach was a trial-and-error and time-consuming process.
We attempted to find a more systematic method by computing and comparing the neutron
cross sections of different materials. An ideal moderator should have a high scatter cross
section and low absorption. Figure 3.10 illustrates the neutron cross sections for various
moderator materials that were found to be either a good or poor moderator for 2.45-MeV
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neutrons. The cross sections included the total scatter, elastic scatter, inelastic scatter, and
absorption at 2.45 MeV. All the materials had relatively negligible absorption cross
sections. However, none of the materials had a prominent scatter cross section. The
simulation results showed that LiF and MgF2 were the optimal materials for fast neutron
moderation, but their scatter cross sections were comparable to those of other materials.
Materials that were found to have better moderating ability (e.g. Al and Fluental™) had
lower scatter cross sections than those that were poor moderators (e.g. CF2 and TiF3).
Further investigation is needed to identify the common characteristics among the
moderator materials and to have a better understanding of epithermal neutron interaction
with matter.

Figure 3.10 Neutron cross sections for various moderator materials at 2.45 MeV.

To satisfy the epithermal recommendation by the IAEA, the DD neutron generator
would require a neutron yield of 5.1 x 1013 n/s. On the other hand, according to the in-
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phantom FOMs and the irradiation time of 1 hour, the neutron yield should be 3.6 x 1013
n/s. With the lower neutron flux, the epithermal flux would be just shy of the IAEA
criterion. Therefore, the desired DD neutron intensity should be the higher value, 5.1 x 1013
n/s, which would reduce the treatment time from 60 to 42 minutes. While the flux of our
current generator is 5 x 109 n/s, study has found that by increasing the deuterium beam
current, along with other technical adjustments, the neutron yield could be enhanced to
1012 n/s.93 In addition, Adelphi Technology Inc. is in the process of developing a multibeam system that combines multiple DD neutron generators to produce a higher neutron
intensity.
The simulated neutron source configuration had been simplified as a point source
in a vacuum casing before the arrival of the actual DD neutron generator in our lab. The
model did not consider the other components of the actual generator, such as a layer of
polyethylene in the beam direction for grounding. This may have an effect on the neutron
spectrum and, therefore, BSA optimization. In order to assess the possible effect of the
simplification, a separate simulation was done using a more complicated neutron source
model. Figure 3.11 shows the neutron spectrum when the addition al components were
added to the neutron source model while the BSA remained the same as in Figure 3.7.
Compared to Figure 3.8, the neutron spectrum has an energy peak at a higher energy, 22
keV, and more fast neutrons. The epithermal neutron flux was reduced to 3.1 x 104 n/cm2s; the thermal-to-epithermal neutron ratio increased to 0.06. The fast neutron dose and the
photon dose increased to 3.6 x 10-12 cGy-Eq/nepi and 3.5 x 10-13 cGy-Eq/nepi, respectively.
By modifying the source configuration, the neutron output was affected considerably, and
the in-air FOMs no longer meet the IAEA recommendations or were in agreement with
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other BNCT neutron sources. It indicates that further simulations should be performed
using the updated source configuration to investigate if a different BSA layout would better
optimize the neutron beam output.

Figure 3.11 Neutron spectrum simulated using the actual DD neutron source layout with
the optimized BSA layout.

In this MCNP study, the goal was to determine a BSA layout that would moderate
the 2.45-MeV DD neutrons to the desired energy range for BNCT of the brain. The neutron
output produced from the optimized layout was evaluated in air at the beam aperture and
in a head phantom. The in-air FOMs either met the IAEA recommendations or were within
the range of existing BNCT facilities, except for the epithermal neutron flux. The inphantom parameters were comparable to those of other BNCT systems. The resulting peak
skin dose was 0.59 Gy-Eq, which was well below the dose tolerance of 18 Gy-Eq.

66
According to the results, the DD neutron yield would need to reach 5.1 x 1013 n/s to satisfy
the epithermal neutron flux requirement and complete irradiation within a reasonable
amount of time. The proposed system showed encouraging results and was capable of
producing a neutron beam with acceptable dosimetric characteristics. Further efforts are
underway to improve the neutron yield to make DD neutron generators a competitive
BNCT neutron source for clinical use.
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CHAPTER 4.

4.1

MCNP DOSE DISTRIBUTIONS

Introduction
While the in-air and in-phantom FOMs provided insights into the properties of the

produced neutron beam of the optimized DD-based BNCT system, the dose distributions
within tissues are still unclear. Previous simulations applied mathematical head phantoms
to assess tissue doses; however, the accuracy of MCNP simulations greatly depend on the
modeling of the phantom and the environment. The MIRD phantom has been used
extensively in the health physics and radiotherapy communities, but the human anatomy is
far too complex to be simplified into several mathematical equations. A more realistic
phantom model will substantially improve MCNP dosimetry calculations and provide more
accurate results. In addition to the average dose and the maximum dose that the tumor and
normal tissues receive, it is also essential to obtain information on what percentage of the
normal tissues receive a certain dose and what the tumor dose coverage looks like. With
an improved phantom model, a dose-volume histogram will provide a better understanding
of the dosimetric characteristics of the DD-based neutron beam. The objective of this study
was to examine the dose distributions in a cadaver-based phantom in MCNP.

4.2
4.2.1

Materials and Methods
VIP-Man
While the MIRD phantom allowed simulation modeling to benchmark beam

parameters and characteristics, it is important to use a more realistic phantom model for
clinical applications. VIP-Man is an imaged-based, whole-body adult male model,
developed by the National Library of Medicine in the Visible Human Project for Monte
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Carlo dose calculations (Figure 4.1).95 The images were of a male cadaver that was
representative of a large population and were implemented into Monte Carlo codes. The
VIP-Man phantom models the anatomical organs that are not represented in the MIRD
phantom and closely resembles an actual human body compared to mathematical models.
There was a total of over 5 million voxels in the whole-body phantom, and the voxel size
was 4 x 4 x 4 mm3. While the region of interest in this study was the brain only, the rest of
the phantom could potentially affect particle transports and was kept intact. The brain
region of the VIP-Man was separated into multiple compartments, which were combined
and tallied together to determine the dose to the whole brain in MCNP. The tissues
consisted of caudate nuclei, lentiform nuclei, thalamus, white matter, lateral ventricle,
corpus callosum, pons, fornix, cerebellum, and gray matter. The total brain region was
comprised of 19,926 voxels and had a volume of 1275.3 cm3.
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Figure 4.1 VIP-Man in 3D view from Xu et al.95

4.2.2

Dose Distribution
The optimized BSA from the previous chapter (Figure 3.7) was used as the neutron

source in this study. The source was positioned behind the VIP-Man phantom. Figure 4.2
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shows a lateral view of the posterior-anterior beam setup. The doses to all 19,926 voxels
were determined and used to generate a dose volume histogram (DVH). The calculated
dose from MCNP were in unit of Gy-Eq per source neutron and were then normalized to
the maximum brain tolerance dose of 12.5 Gy-Eq. Simulations were performed using
MCNP6 version 1.0, instead of MCNPX, due to the greater limit on the number of histories
in MCNP6.

Figure 4.2 Lateral view of the simulation setup for a posterior-anterior beam angle.
4.3

Results
Figure 4.3 shows the DVH for the whole brain. The dose was normalized to the

maximum tolerance dose of 12.5 Gy-Eq. The minimum dose that the brain obtained was
1.2 Gy-Eq. The average brain dose was 5.3 Gy-Eq.
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Figure 4.3 A dose-volume histogram from irradiation with the optimized DD-based
BNCT system.
4.4

Discussion and Conclusion
The purpose of this chapter study was to examine the dose distributions in a realistic

boy phantom from BNCT irradiation with the DD-based BNCT system optimized in the
previous chapter. The DVH for the brain was normalized to the tolerance dose of 12.5 GyEq. The results showed that the maximum brain dose was, thus, 12.5 Gy-Eq, the minimum
dose was 1.2 Gy-Eq, and the average dose was 5.3 Gy-Eq.
The main disadvantage of determining dose distributions in MCNP is that it is very
time-consuming and computationally expensive. Despite using Purdue’s high-performance
research computing system with 10-core Intel processors, it still took approximately 200
hours to tally all the voxels in the brain. Due to the small size of the voxels (4 x 4 x 4 mm3),
some of the relative errors in the voxels were significantly greater than 5%. To reduce the
uncertainties to an acceptable level, the number of histories would need to increase by at
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least one order of magnitude, potentially increasing the computational time to 2,000 hours.
Instead of using the conventional central processing units, graphics processing unit (GPU)
may improve the efficiency in computationally intensive tasks, such as MCNP. GPU-based
MCNP has been shown to be 69 to 87 times faster than the conventional CPU-based and
generated results that were in agreement with CPU-based.96 Another alternative is to
increase the voxel size, or combine several voxels into one, hence the number of particles
per voxel is higher and the statistical uncertainty is reduced. The downside of this method
is that, with large voxels, the contour of the internal organs may not be well preserved,
which may in turns affect the dose calculations. It is also hard to manipulate or change the
VIP-Man input file due to the large number of voxels involved. A phantom with variable
voxel sizes may be more advantageous for reducing the computational time.97 The “multivoxel” model has smaller voxels, or higher resolution, near the beam entrance and larger
voxels, or coarse resolution, distant from the beam entrance. This approach will allow more
accurate dose calculations in regions of interest and increase efficiency by reducing the
computational effort in the surrounding regions.
Due to the long computational time, only the brain DVH was obtained. Future
works can expand to other normal tissues, such as the scalp and the cranium. It would be
ideal to have tumor tissues incorporated in the phantom model to examine the dose
distribution within the tumor as well. However, the VIP-Man has only normal tissues, and
the user will have to introduce a voxel or voxels of tumor within the brain. It is difficult to
objectively decide what size and location of the tumor to use in the simulations and may
require numerous simulations to cover different scenarios. Actual patient data from CT or
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MRI images would be beneficial but will require converting and importing those data into
MCNP format.
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CHAPTER 5.

DISCUSSION

While the current standard of care for glioblastoma patients is well established and
proven to improve patient survival compared to decades ago. However, the median survival
remains dismal and has not changed significantly in recent years. BNCT offers a biological
component to the treatment and allows targeting of the microscopic tumor cells that
conventional treatments are unable to eradicate. The two major challenges that BNCT
currently encounters are the development of B-10 compounds and the lack of a clinically
appropriate neutron source, hindering research progress and interest in BNCT. The
dilemma between the two issues of B-10 drug improvement and neutron source
development is that they are interconnected, meaning that each side is dependent on the
other to show progress. The two clinical compounds, BPA and BSH, have be demonstrated
to provide promising B-10 delivery and preferential accumulation in the tumor cells. While
continuous progress is still underway to further improve the drugs, the B-10 compound
issue is the less pressing of the two. The focus of this dissertation work was to help resolve
the neutron source problem that is troubling the BNCT community.
A DD neutron generator offers several advantages over nuclear reactors and large
particle accelerators in terms of cost, size, installation and modification process. Although
the construction of proton accelerators continues to expand, the cost to build and maintain
the facility is several orders of magnitude greater than that for a DD neutron generator.
Accelerators also face technical difficulties that are yet to be overcome. With less capital
expenses and space, DD neutron generators can be more widespread, accessible to patient
populations, and offered to all forms of clinics and institutions. As more systems are
installed, data collection and patient recruitment will be enhanced as well.
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The simulation results of the optimized DD neutron generator-based BNCT system
demonstrated that DD neutron generators could produce comparable dosimetric properties
as nuclear reactors and large accelerators. Based on the in-air evaluation, the epithermal
neutron flux was insufficient by four orders of magnitude. However, this was based on
several assumptions, including that the tumor-to-brain boron ratio was 3.5 and only one
field, one fraction was applied. The required increase of four orders of magnitude is not
solely dependent on the neutron flux alone. If further compound development is able to
increase the boron ratio to 10 or if multiple fields or fractions are applied, the DD neutron
flux requirement will be reduced by half or more. The in-phantom parameters presented
similar results as other BNCT neutron sources, except for the dose rate, which is also due
to the inadequate DD neutron flux. The AD of the proposed system was 12.5 cm,
suggesting that the neutron beam could treat tumors up to 12.5 cm deep. However, since
the dimension of a typical human head is 20 cm long, beam penetration greater than 10 cm
may be redundant because parallel-opposed beams can be used. The maximum skin dose
delivered by the proposed system was 0.6 Gy-Eq, which was substantially lower than the
tolerance limit. Early clinical trials reported that patients exhibited radiation dermatitis of
the scalp, and the results from this work demonstrated that radiation-induced toxicities in
the skin would not be an issue.
Although the proposed system produced comparable dosimetric characteristics as
other BNCT types of neutron sources, the neutron flux of DD neutron generators is still
lackluster. While system and software development of DD neutron generators is beyond
the scope of this dissertation, feedbacks and suggestions are provided to the manufacturer.
Currently BNCT clinical trials have not shown a significant advantage in the median
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survival of glioblastoma patients treated with BNCT. However, this innovative technique
could be administered in conjunction with surgery or other treatment modalities. Study has
found that BNCT with radiotherapy significantly increased patient survival.98
The overall goal of this dissertation is to investigate and design the use of a compact
DD neutron generator for BNCT of the brain. Given the present challenges that BNCT
encounters, this dissertation presented an alternative neutron source that is clinically
feasible and friendly. With sufficient development and research, DD neutron generators
can become a competitive neutron source that can help address deficiencies in current
clinical practice and stimulate industrial interest and institutional commitment.
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CHAPTER 6.

OVERALL CONCLUSION

The overall objective of this dissertation research was to design a DD neutron
generator-based BNCT system and to examine the dosimetric properties of the neutron
output. In the first specific aim, the effect of neutron beam energy on tissue dose was
investigated. Epithermal neutrons between the energy of 0.5 eV and 10 keV were the
optimal energy for BNCT of brain tumors. In terms of tumor dose, epithermal neutrons
were able to utilize the advantages of the high LET particles to the maximum while fast
neutrons delivered radiation dose via neutron particles. With epithermal neutrons,
approximately half of the brain dose originated from photons. However, as the neutron
energy increased to the MeV range, both the brain and the tumor obtained the same amount
of dose from neutrons. The dose ratio between the tumor and the brain was found to be
maximized in the epithermal energy range as well as the AD and AR.
The second specific aim was to design a BSA for a DD neutron source to moderate
the 2.45-MeV DD neutrons to the epithermal range as well as reducing the levels of
background radiation. The optimized BSA layout had the following configuration: 45 cm
of Li7F and 10 cm of MgF2 for the moderator, 30 cm of lead for the reflector, 10 cm of lead
for the collimator, and 0.02 cm of Cd-113 for the thermal filter. Comparing the in-air FOMs
with the IAEA recommendations, the epithermal neutron flux was insufficient by about
four orders of magnitude, but the thermal-to-epithermal neutron ratio, the fast neutron dose
per epithermal neutron, and the photon dose per epithermal neutron were acceptable. The
in-phantom FOMs, e.g. AD and AR, were comparable to data from existing BNCT
facilities. While the ADDR was lacking compared to others, however, if the DD neutron
generator had adequate neutron flux, the ADDR would be in agreement with or higher than
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some of the current facilities. For the DD neutron generator to be a feasible BNCT neutron
source, the neutron flux would need to be at least 5.1 x 1013 n/s.
The goal of the third specific aim was to examine the dose distributions from
irradiations with the neutron beam of the optimized BNCT system. The phantom model
was the VIP-Man, which was an imaged-based, whole-body model based on a male
cadaver. The DVH for the brain showed that the maximum dose was 12.5 Gy-Eq, the
minimum dose was 1.4 Gy-Eq, and the average dose was 5.3 Gy-Eq.
In the future, the BSA layout for our most current DD neutron generator can be
further optimized to account for any structural differences that the simulation model did
not include. Since this dissertation research focused on computer simulations of the DD
neutron generator, experiments to verify the simulation results would be beneficial, such
as dose measurements in air and in phantom, and neutron spectrum determination using
activation foils. Future work may also investigate methods to reduce the MCNP
computational time without sacrificing the accuracy of the results.
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APPENDIX MCNP BSA INPUT FILE

c Male Adult Head
c BSA moderator: 45 cm LiF, 10 cm MgF2
c Cadmium filter
c 30 cm Pb reflector
c Pb collimator
c --------------------------- Cells of the phantom -------------------------1 0 999

$void

5 1 -0.001205
(-999 ((2203 3805 -2202):(((2207 -2206):(2206 2207)) 2202 -2205)
:(2107 2205)) #15 #20 #8 #10 #11 #12 #30 #40 #41 #42 #43 #44)
:(-999 -3805 #15 #20 #8 #10 #11 #12 #30 #40 #41 #42 #43 #44)
c ----------------------------- Neutron Generator --------------------------15 2 -2.6989 (11 -12 201 -202 -14 13)
20 2 -2.6989 (102 -12 202 -110 13 -14):(11 -101 202 -110 13 -14)
:(11 -12 202 -110 -14 104):(11 -12 202 -110 13 -103)
:(11 -12 110 -10 13 -14)
8 0 (101 -102 202 -110 103 -104)
c ------------------------------- Moderators ---------------------------------10 8 -3.148 (11 -12 13 -14 105 -106) #40 #41 #42 #43 #44
11 12 -2.65 (11 -12 13 -14 106 -201) #40 #41 #42 #43 #44
c -------------------------------- Reflector -----------------------------------12 9 -11.34 (-11 108 31 -111 112 -113):(12 -109 31 -111 112 -113)

$air in sphere
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:(11 -12 31 -111 14 -113):(11 -12 31 -111 -13 112)
:(11 -12 10 -111 13 -14)
c ---------------------------------- Filter -----------------------------------30 4 -8.65 (11 -12 30 -105 13 -14)
c ------------------------------- Collimator -------------------------------40 9 -11.34 (43 -44 31 -14 -40)

$Upper yz

41 9 -11.34 (43 -44 31 13 42)

$Lower yz

42 9 -11.34 (-12 -45 31 46 -47)

$Upper xy

43 9 -11.34 (11 48 31 46 -47)

$Lower xy

44 9 -11.34 (11 -43 31 -41 -14 47 -49):(-12 44 31 -41 -14 47 50)
:(11 -43 31 -41 13 -46 51):(-12 44 31 -41 13 -46 -52)

$Corner quadrants

c --------------------------------- Phantom --------------------------------100 7 -1.03 ((-2201 3805 -2202):
(((-2207 -2206):(2206 -2204)) 2202 -2205):(-2209 2205))
#141 #471
#224 #225 #226
#700 #701 #702 #703 #704 #705 #706 #707 #708 #709 #710
#711 #712 #713 #714 #715 #716 #717 #718 #719 #720 #721
#722 #723 #724 #725 #726 #727 #728 #729 #730 #731 #732

$normal tissue

141 15 -1.04 (-1402 2205 #700 #701 #702 #703 #704 #705 #706 #707 #708 #709
#710 #711 #712 #713 #714 #715 #716 #717 #718 #719 #720 #721 #722
#723 #724 #725 #726 #727 #728 #729 #730 #731):(-1404 -1408 -2205)
#700 #701 #702 #703 #704 #705 #706 #707 #708 #709
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#710 #711 #712 #713 #714 #715 #716 #717 #718 #719 #720 #721 #722
#723 #724 #725 #726 #727 #728 #729 #730 #731 #732
224 6 -1.09 2201 -2203 -2202 3805

$brain
$neck skin

225 6 -1.09 2204 -2207 2206 -2205 2202 #732
226 6 -1.09 2209 -2107 2205 #732

$scalp

471 16 -1.61 (4701 -2209 2205):(-2205 4703 -4704 -4707)
:(-2205 4706 -4707 -4703)
c ------------------------------ Tally cells -------------------------------700 15 -1.04 (-7000 -7001 7002)
701 15 -1.04 (-7000 -7002 7003)
702 15 -1.04 (-7000 -7003 7004)
703 15 -1.04 (-7000 -7004 7005)
704 15 -1.04 (-7000 -7005 7006)
705 15 -1.04 (-7000 -7006 7007)
706 15 -1.04 (-7000 -7007 7008)
707 15 -1.04 (-7000 -7008 7009)
708 15 -1.04 (-7000 -7009 7010)
709 15 -1.04 (-7000 -7010 7011)
710 15 -1.04 (-7000 -7011 7012)
711 15 -1.04 (-7000 -7012 7013)
712 15 -1.04 (-7000 -7013 7014)
713 15 -1.04 (-7000 -7014 7015)
714 15 -1.04 (-7000 -7015 7016)

$cranium
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715 15 -1.04 (-7000 -7016 7017)
716 15 -1.04 (-7000 -7017 7018)
717 15 -1.04 (-7000 -7018 7019)
718 15 -1.04 (-7000 -7019 7020)
719 15 -1.04 (-7000 -7020 7021)
720 15 -1.04 (-7000 -7021 7022)
721 15 -1.04 (-7000 -7022 7023)
722 15 -1.04 (-7000 -7023 7024)
723 15 -1.04 (-7000 -7024 7025)
724 15 -1.04 (-7000 -7025 7026)
725 15 -1.04 (-7000 -7026 7027)
726 15 -1.04 (-7000 -7027 7028)
727 15 -1.04 (-7000 -7028 7029)
728 15 -1.04 (-7000 -7029 7030)
729 15 -1.04 (-7000 -7030 7031)
730 15 -1.04 (-7000 -7031 7032)
731 15 -1.04 (-7000 -7032 7033)
732 6 -1.09 (2209 -2107 7034 -7035 2205 -7037 2206)
:(2204 -2207 7034 -7035 -2205 7036 2206)

$Skin tally

c ----------------------- Surfaces of the phantom ---------------------999 so 300

$MCNP compatible

c -------------------------- Neutron Generator --------------------------
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101 px -15.1765
102 px 15.1765
103 pz -16.224
104 pz 16.224
110 py 86.12
10

py 88.025

11

px -17.5895

12

px 17.5895

13

pz -18.637

14

pz 18.637

c ------------------------- Moderator & Reflector ---------------------105 py 1
106 py 11
201 py 56
202 py 56.3175
108 px -47.5895
109 px 47.5895
111 py 118.025
112 pz -48.637
113 pz 48.637
114 px -1
115 px 1
116 pz 1
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117 pz -1
c ---------------------------- Filter ------------------------30

py 0.98

31

py 1

c ------------------------- Collimator ---------------------40

p 0 1.2637 -1 -4.7363

41

py 11

42

p 0 -1.2637 -1 4.7363

43

px -6

44

px 6

45

p -1 1.15895 0 -4.84105

46

pz -6

47

pz 6

48

p -1 -1.15895 0 4.84105

49

p 126.37 146.4565115 -115.895 -1307.1334885

50

p 126.37 -146.4565115 115.895 1307.1334885

51

p -126.37 -146.4565115 -115.895 1307.1334885

52

p -126.37 146.4565115 115.895 -1307.1334885

c --------------------------- Brain --------------------------1401 sq .026699 .014945 .057233 0 0 0 -1 0 -13 0

$upper surface of inner side

1402 sq .019726 .011866 .037268 0 0 0 -1 0 -13 0
1403 sq .026699 .014945 .035870 0 0 0 -1 0 -13 0
1404 sq .019726 .011866 .025356 0 0 0 -1 0 -13 0

$lower surface of inner side
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1407 p 0 -0.645477 -1 13.671431

$inner surface of the plane

1408 p 0 -0.684069 -1 15.172207
c --------------------------- Head --------------------------2201 c/z 0 -11.8 5.81

$neck, cylindar surface

2202 pz -12.8

$neck, upper z plane

3805 pz -18

$neck, lower z plane

2203 c/z 0 -11.8 6.01

$skin of neck

2204 sq 0.016692 0.010412 0 0 0 0 -1 0 -13 0

$face, cylindar surface

2205 pz 0

$face, upper z plane

2206 py -8.2

$face, right y plane

2207 sq 0.015862 0.01 0 0 0 0 -1 0 -13 0

$skin of face

2209 sq 0.016692 0.010412 0.029727 0 0 0 -1 0 -13 0

$top of head

2107 sq 0.015862 0.01 0.027778 0 0 0 -1 0 -13 0 $skin of top head
4701 sq .019237 .011637 .036006 0 0 0 -1 0 -13 0

$inner upper skull

4703 sq .019237 .011637 .024645 0 0 0 -1 0 -13 0

$inner lower skull

4704 sq 0.016692 0.010412 .021004 0 0 0 -1 0 -13 0

$outer lower skul

4706 p 0 -0.687163 -1 15.301489

$inner skull plane

4707 p 0 -0.704082 -1 16.052246

$outer skull plane

c ------------------------- Tally cells ---------------------7000 c/y 0 0 1
7001 py -4
7002 py -4.5
7003 py -5
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7004 py -5.5
7005 py -6
7006 py -6.5
7007 py -7
7008 py -7.5
7009 py -8
7010 py -8.5
7011 py -9
7012 py -9.5
7013 py -10
7014 py -10.5
7015 py -11
7016 py -11.5
7017 py -12
7018 py -12.5
7019 py -13
7020 py -13.5
7021 py -14
7022 py -14.5
7023 py -15
7024 py -15.5
7025 py -16
7026 py -16.5

87
7027 py -17
7028 py -17.5
7029 py -18
7030 py -18.5
7031 py -19
7032 py -19.5
7033 py -20
7034 px -0.04375
7035 px 0.04375
7036 pz -0.04375
7037 pz 0.04375

mode n p a
c ----------------------------------------- Air -------------------------------------------------m1 6000 -.0001 7014 -.7553 8016 -.2318 18000 -.0128 gas=1
c ------------------------------------------------------------------------------------------------m2 13027.70c

-1 $ Aluminum

c ------------------------------- Cadmium (8.65 g/cm^3) ----------------------------------m4 48000 -1
c ------------------- ICRU skin with boron (22.5 microg/g of tissue) --------------------m6 1001 -.10
5010 -.0000225
6000 -.204
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7014 -.042
8016 -.645
11023 -.002
15031 -.001
16032 -.002
17000 -.003
19000 -.001
c ----------------- ICRU soft tissue with boron (15 microg/g of tissue) ----------------m7 1001 -.105
5010 -.000015
6000 -.256
7014 -.027
8016 -.602
11023 -.001
15031 -.002
16032 -.003
17000 -.002
19000 -.002
c --------------------------------- MgF2 (3.148 g/cm^3) --------------------------------m8 12024 -0.390117
9019 -0.609883
c --------------------------------- Lead (11.34 g/cm^3) ---------------------------------m9 82000 -1
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c ---------------------------------- LiF (2.65 g/cm^3) -----------------------------------m12 3007 0.5
9019 0.5
c --------------- ICRU brain tissue with boron (15 microg/g of tissue) -----------m15 1001 -.107
5010 -.000015
6000 -.145
7014 -.022
8016 -.712
11023 -.002
15031 -.004
16032 -.002
17000 -.003
19000 -.003
c ---------------------------------- ICRU cranium -----------------------------------m16 1001 -.05
6000 -.212
7014 -.04
8016 -.435
11023 -.001
12000 -.002
15031 -.081
16032 -.003
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20000 -.176
c ------------------------------------ Source Card -----------------------------------c ---------------------------------- Source Position ---------------------------------sdef par=n x=d1 y=d2 z=d3 erg=2.45
si1 -1.905 1.905
sp1 0 1.0
si2 56.8175 57.0715
sp2 0 1.0
si3 -1.905 1.905
sp3 0 1.0
imp:n,p,a,e 0 1 51r
cut:a j 0
prdmp j j -1
c ------------------------------------- Tallies --------------------------------------fc114 Photon fluence to photon kerma in cGy_Zamenhof
f114:P 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716
717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732
sd114 1.57 31r 0.035
de114 1E-3 2E-3 5E-3 1E-2 2E-2 5E-2 1E-1 2E-1 5E-1 1 2 5 10 20
df114 5.99E-8 1.8E-8 3.24E-9 7.75E-10 1.75E-10 3.42E-11 4.04E-11
9.46E-11 2.63E-10 4.94E-10 8.29E-10 1.52E-9 2.48E-9
4.38E-9
fc124 Neutron fluence to alpha kerma in cGy/ppm_Caswell
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f124:N 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716
717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732
sd124 1.57 31r 0.035
de124 .253E-7 .36E-7 .63E-7 .11E-6 .2E-6 .36E-6 .63E-6 .11E-5
.2E-5 .36E-5 .63E-5 .11E-4 .2E-4 .36E-4 .63E-4 .11E-3
.2E-3 .36E-3 .63E-3 .11E-2 .2E-2 .36E-2 .63E-2 .11E-1
.2E-1 .36E-1 .63E-1 .82E-1 .86E-1 .9E-1 .94E-1 .96E-1
.105 .115 .125 .135 .145 .155 .165 .175 .185 .195 .21
.23 .25 .27 .29 .31 .33 .35 .37 .39 .42 .46 .5 .54 .58
.62 .66 .7 .74 .78 .82 .86 .9 .94 .98 1.05 1.15 1.25
1.35 1.45 1.55 1.65 1.75 1.85 1.95 2.1 2.3 2.5
df124 7.95E-12 6.75E-12 5.1E-12 3.85E-12 2.86E-12 2.13E-12 1.61E-12
1.22E-12 9.05E-13 6.75E-13 5.1E-13 3.84E-13 2.85E-13 2.12E-13
1.6E-13 1.21E-13 8.95E-14 6.65E-14 5E-14 3.78E-14 2.8E-14
2.08E-14 1.57E-14 1.19E-14 8.9E-15 6.8E-15 5.4E-15 4.84E-15
4.76E-15 4.69E-15 4.62E-15 4.56E-15 4.46E-15 4.33E-15 4.21E-15
4.11E-15 4.02E-15 3.94E-15 3.86E-15 3.79E-15 3.73E-15 3.67E-15
3.59E-15 3.49E-15 3.39E-15 3.3E-15 3.21E-15 3.14E-15 3.08E-15
3.04E-15 3.03E-15 3.09E-15 3.54E-15 3.47E-15 3.13E-15 2.93E-15
2.73E-15 2.56E-15 2.41E-15 2.31E-15 2.24E-15 2.19E-15 2.17E-15
2.15E-15 2.14E-15 2.14E-15 2.13E-15 2.17E-15 2.41E-15 3.27E-15
3.31E-15 3.08E-15 3.23E-15 3.6E-15 4.33E-15 4.54E-15 4.35E-15
4.11E-15 3.73E-15 4.49E-15
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fc134 Neutron fluence to neutron kerma in cGy
f134:N 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716
717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732
sd134 1.57 31r 0.035
de134 2.53E-8 3.6E-8 6.3E-8 1.1E-7 2E-7 3.6E-7 6.3E-7 1.1E-6
2E-6 3.6E-6 6.3E-6 1.1E-5 2E-5 3.6E-5 6.3E-5 1.1E-4
2E-4 3.6E-4 6.3E-4 1.1E-3 2E-3 3.6E-3 6.3E-3 1.1E-2
2E-2 3.6E-2 6.3E-2 8.2E-2 8.6E-2 9E-2 9.4E-2 9.8E-2
1.05E-1 1.15E-1 1.25E-1 1.35E-1 1.45E-1 1.55E-1 1.65E-1
1.75E-1 1.85E-1 1.95E-1 2.1E-1 2.3E-1 2.5E-1 2.7E-1
2.9E-1 3.1E-1 3.3E-1 3.5E-1 3.7E-1 3.9E-1 4.2E-1 4.6E-1
5E-1 5.4E-1 5.8E-1 6.2E-1 6.6E-1 7E-1 7.4E-1 7.8E-1
8.2E-1 8.6E-1 9E-1 9.4E-1 9.8E-1 1.05 1.15 1.25 1.35
1.45 1.55 1.65 1.75 1.85 1.95 2.1 2.3 2.5
df134 2.18E-11 1.85E-11 1.39E-11 1.05E-11 7.83E-12 5.83E-12 4.42E-12 3.34E-12
2.5E-12 1.88E-12 1.46E-12 1.17E-12 9.99E-13 9.69E-13 1.11E-12 1.5E-12
2.37E-12 4.03E-12 6.8E-12 1.17E-11 2.1E-11 3.74E-11 6.43E-11 1.08E-10
1.89E-10 3.12E-10 4.85E-10 5.86E-10 6.06E-10 6.25E-10
6.44E-10 6.62E-10 6.93E-10 7.36E-10 7.77E-10 8.15E-10
8.53E-10 8.88E-10 9.21E-10 9.55E-10 9.85E-10 1.01E-9
1.06E-9 1.12E-9 1.16E-9 1.22E-9 1.27E-9 1.32E-9 1.36E-9
1.41E-9 1.46E-9 1.52E-9 1.64E-9 1.67E-9 1.66E-9 1.71E-9
1.77E-9 1.83E-9 1.9E-9 1.95E-9 2E-9 2.06E-9 2.11E-9
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2.17E-9 2.23E-9 2.32E-9 2.48E-9 2.53E-9 2.53E-9 2.63E-9
2.72E-9 2.78E-9 2.85E-9 2.96E-9 3E-9 3.12E-9 3.15E-9
3.25E-9 3.31E-9 3.44E-9
nps
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